WordNet

an impairment of health or a condition of abnormal functioning
caused by or altered by or manifesting disease or pathology; "diseased tonsils"; "a morbid growth"; "pathologic tissue"; "pathological bodily processes" (同)morbid, pathologic, pathological
United States physician who specialized in diseases of the intestines; he was the first to describe regional ileitis which is now known as Crohns disease (1884-1983) (同)Burrill Bernard Crohn

PrepTutorEJDIC

certificate of deposit / (また『C.D.』)Civil Defense民間防衛
(体の)『病気』,疾患 / (精神・道徳などの)病気,病弊
女性の話術芸人 =diseur
病気にかかった / 病的な,不健全な(morbid)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/10/31 02:19:43」(JST)

wiki en

Crohn's disease, also known as Crohn syndrome and regional enteritis, is a type of inflammatory bowel disease (IBD) that may affect any part of the gastrointestinal tract from mouth to anus.^[2] Symptoms often include: abdominal pain, diarrhea (which may be bloody if inflammation is severe), fever and weight loss.^[1]^[2] Other complications may occur outside the gastrointestinal tract and include: anemia, skin rashes, arthritis, inflammation of the eye, and tiredness. The skin rashes may be due to infections as well as pyoderma gangrenosum or erythema nodosum. Bowel obstruction also commonly occurs and those with the disease are at greater risk of bowel cancer.^[1]

Crohn's disease is caused by a combination of environmental, immune and bacterial factors in genetically susceptible individuals.^[3]^[4]^[5] It results in a chronic inflammatory disorder, in which the body's immune system attacks the gastrointestinal tract possibly directed at microbial antigens.^[4]^[6] While Crohn's is an immune related disease, it does not appear to be an autoimmune disease (in that the immune system is not being triggered by the body itself).^[7] The exact underlying immune problem is not clear; however, it may be an immunodeficiency state.^[6]^[8]^[9] About half of the overall risk is related to genetics with more than 70 genes found to be involved.^[1]^[10] Tobacco smokers are two times more likely to develop Crohn's disease than nonsmokers.^[11] It also often begins after gastroenteritis. Diagnosis is based on a number of findings including: biopsy and appearance of the bowel wall, medical imaging and description of the disease. Other conditions that can present similarly include: irritable bowel syndrome and Behcet's disease.^[1]

There are no medications or surgical procedures that can cure Crohn's disease. Treatment options help with symptoms, maintain remission, and prevent relapse. In those newly diagnosed a corticosteroid may be used for a brief period of time to quickly improve the disease with another medication such as either methotrexate or a thiopurine used to prevent recurrence. An important part of treatment is the stopping of smoking among those who do. One in five people with the disease are admitted to hospital each year, and half of those with the disease will require surgery for the disease at some point over a ten year period. While surgery should be used as little as possible, it is necessary to address some abscesses, certain bowel obstructions, and cancers. Checking for bowel cancer via colonoscopy is recommended every few years, starting eight years after the disease has begun.^[1]

Crohn's disease affects about 3.2 per 1,000 people in Europe and North America.^[12] It is less common in Asia and Africa.^[13]^[14] It has historically been more common in the developed world.^[15] Rates have, however, been increasing, particularly in the developing world since the 1970s.^[14]^[15] Inflammatory bowel disease resulted in 35,000 deaths in 2010^[16] and those with Crohn's disease have a slightly reduced life expectancy.^[1] It tends to start in the teens and twenties, although it can occur at any age.^[1]^[2] Males and females are equally affected.^[2] The disease was named after gastroenterologist Burrill Bernard Crohn, who, in 1932, together with two other colleagues at Mount Sinai Hospital in New York, described a series of patients with inflammation of the terminal ileum of the small intestine, the area most commonly affected by the illness.^[17]

1 Signs and symptoms
- 1.1 Gastrointestinal
- 1.2 Systemic
- 1.3 Extraintestinal
2 Cause
- 2.1 Genetics
- 2.2 Immune system
- 2.3 Microbes
- 2.4 Environmental factors
3 Pathophysiology
4 Diagnosis
- 4.1 Classification
- 4.2 Endoscopy
- 4.3 Radiologic tests
- 4.4 Blood tests
- 4.5 Comparison with ulcerative colitis
5 Management
- 5.1 Lifestyle changes
- 5.2 Medication
- 5.3 Surgery
- 5.4 Alternative medicine
6 Prognosis
- 6.1 Complications
7 Epidemiology
8 History
9 Research
10 References
11 External links

Signs and symptoms

Signs and symptoms
[ v t e ]	Crohn's disease	Ulcerative colitis
Defecation	Often porridge-like^[18], sometimes steatorrhea	Often mucus-like and with blood^[18]
Tenesmus	Less common^[18]	More common^[18]
Fever	Common^[18]	Indicates severe disease^[18]
Fistulae	Common^[19]	Seldom
Weight loss	Often	More seldom

Gastrointestinal

Patients with Crohn's can have aphthous ulcers involving mouth.

Many people with Crohn's disease have symptoms for years prior to the diagnosis.^[20] The usual onset is between 15 and 30 years of age, but can occur at any age.^[21] Because of the 'patchy' nature of the gastrointestinal disease and the depth of tissue involvement, initial symptoms can be more subtle than those of ulcerative colitis. People with Crohn's disease experience chronic recurring periods of flare-ups and remission.^[22]

Abdominal pain may be the initial symptom of Crohn's disease. It is often accompanied by diarrhea, especially in those who have had surgery. The diarrhea may or may not be bloody. The nature of the diarrhea in Crohn's disease depends on the part of the small intestine or colon involved. Ileitis typically results in large-volume, watery feces. Colitis may result in a smaller volume of feces of higher frequency. Fecal consistency may range from solid to watery. In severe cases, an individual may have more than 20 bowel movements per day and may need to awaken at night to defecate.^[1]^[23]^[24]^[25] Visible bleeding in the feces is less common in Crohn's disease than in ulcerative colitis, but may be seen in the setting of Crohn's colitis.^[1] Bloody bowel movements typically come and go, and may be bright or dark red in color. In the setting of severe Crohn's colitis, bleeding may be copious.^[23] Flatulence and bloating may also add to the intestinal discomfort.^[23]

Symptoms caused by intestinal stenosis are also common in Crohn's disease. Abdominal pain is often most severe in areas of the bowel with stenoses. Persistent vomiting and nausea may indicate stenosis from small bowel obstruction or disease involving the stomach, pylorus, or duodenum.^[23] Although the association is greater in the context of ulcerative colitis, Crohn's disease may also be associated with primary sclerosing cholangitis, a type of inflammation of the bile ducts.^[26]

Perianal discomfort may also be prominent in Crohn's disease. Itchiness or pain around the anus may be suggestive of inflammation, fistulization or abscess around the anal area^[1] or anal fissure. Perianal skin tags are also common in Crohn's disease.^[27] Fecal incontinence may accompany perianal Crohn's disease. At the opposite end of the gastrointestinal tract, the mouth may be affected by non-healing sores (aphthous ulcers). Rarely, the esophagus, and stomach may be involved in Crohn's disease. These can cause symptoms including difficulty swallowing (dysphagia), upper abdominal pain, and vomiting.^[28]

Systemic

Crohn's disease, like many other chronic, inflammatory diseases, can cause a variety of systemic symptoms.^[1] Among children, growth failure is common. Many children are first diagnosed with Crohn's disease based on inability to maintain growth.^[29] As it may manifest at the time of the growth spurt in puberty, up to 30% of children with Crohn's disease may have retardation of growth.^[30] Fever may also be present, though fevers greater than 38.5 ˚C (101.3 ˚F) are uncommon unless there is a complication such as an abscess.^[1] Among older individuals, Crohn's disease may manifest as weight loss, usually related to decreased food intake, since individuals with intestinal symptoms from Crohn's disease often feel better when they do not eat and might lose their appetite.^[29] People with extensive small intestine disease may also have malabsorption of carbohydrates or lipids, which can further exacerbate weight loss.^[31]

Extraintestinal

Erythema nodosum on the back of a person with Crohn's disease

In addition to systemic and gastrointestinal involvement, Crohn's disease can affect many other organ systems.^[32] Inflammation of the interior portion of the eye, known as uveitis, can cause blurred vision and eye pain, especially when exposed to light (photophobia).^[33] Inflammation may also involve the white part of the eye (sclera), a condition called episcleritis.^[33] Both episcleritis and uveitis can lead to loss of vision if untreated.

Crohn's disease that affects the ileum may result in an increased risk for gallstones. This is due to a decrease in bile acid resorption in the ileum and the bile gets excreted in the stool. As a result, the cholesterol/bile ratio increases in the gallbladder, resulting in an increased risk for gallstones.^[33]

Crohn's disease is associated with a type of rheumatologic disease known as seronegative spondyloarthropathy.^[33] This group of diseases is characterized by inflammation of one or more joints (arthritis) or muscle insertions (enthesitis).^[33] The arthritis in Crohn's disease can be divided into two types. The first type affects larger weight-bearing joints such as the knee (most common), hips, shoulders, wrists, or elbows.^[33] The second type symmetrically involves five or more of the small joints of the hands and feet.^[33] The arthritis may also involve the spine, leading to ankylosing spondylitis if the entire spine is involved or simply sacroiliitis if only the sacroiliac joint is involved.^[33] The symptoms of arthritis include painful, warm, swollen, stiff joints and loss of joint mobility or function.^[22]

Pyoderma gangrenosum on the leg of a person with Crohn's disease

Crohn's disease may also involve the skin, blood, and endocrine system. The most common type of skin manifestation, erythema nodosum, presents as raised, tender red nodules usually appearing on the shins.^[33]^[34] Erythema nodosum is due to inflammation of the underlying subcutaneous tissue, and is characterized by septal panniculitis.^[34] Another skin lesion, pyoderma gangrenosum, is typically a painful ulcerating nodule. Crohn's disease also increases the risk of blood clots;^[33] painful swelling of the lower legs can be a sign of deep venous thrombosis, while difficulty breathing may be a result of pulmonary embolism. Autoimmune hemolytic anemia, a condition in which the immune system attacks the red blood cells, is also more common in Crohn's disease and may cause fatigue, a pale appearance, and other symptoms common in anemia. Clubbing, a deformity of the ends of the fingers, may also be a result of Crohn's disease. Finally, Crohn's disease increases the risk of osteoporosis, or thinning of the bones.^[33] Individuals with osteoporosis are at increased risk of bone fractures.^[35]

People with Crohn's disease often have anemia due to vitamin B12, folate, iron deficiency, or due to anemia of chronic disease.^[36]^[37] The most common is iron deficiency anemia^[36] from chronic blood loss, reduced dietary intake, and persistent inflammation leading to increased hepcidin levels, restricting iron absorption in the duodenum.^[37] As Crohn's disease most commonly affects the terminal ileum where the vitamin B12/intrinsic factor complex is absorbed, B12 deficiency may be seen.^[37] This is particularly common after surgery to remove the ileum.^[36] Involvement of the duodenum and jejunum can impair the absorption of many other nutrients including folate. If Crohn's disease affects the stomach, production of intrinsic factor can be reduced.

Crohn's disease can also cause neurological complications (reportedly in up to 15%).^[38] The most common of these are seizures, stroke, myopathy, peripheral neuropathy, headache and depression.^[38]

People with Crohn's often also have issues with small bowel bacterial overgrowth syndrome, which has similar symptoms.^[39]

In the oral cavity people with Crohn's may develop cheilitis granulomatosa and other forms of orofacial granulomatosis, pyostomatitis vegetans, recurrent aphthous stomatitis, geographic tongue and migratory stomatitis in higher prevalence than the general population.^[40]

Cause

Risk factors
[ v t e ]	Crohn's disease	Ulcerative colitis
Smoking	Higher risk for smokers	Lower risk for smokers^[41]
Age	Usual onset between 15 and 30 years^[42]	Peak incidence between 15 and 25 years

While the exact cause is unknown,^[43] Crohn's disease seems to be due to a combination of environmental factors and genetic predisposition.^[44] Crohn's is the first genetically complex disease in which the relationship between genetic risk factors and the immune system is understood in considerable detail.^[45] Each individual risk mutation makes a small contribution to the overall risk of Crohn's (approximately 1:200). The genetic data, and direct assessment of immunity, indicates a malfunction in the innate immune system.^[46] In this view, the chronic inflammation of Crohn's is caused when the adaptive immune system tries to compensate for a deficient innate immune system.^[47]

Genetics

Schematic of NOD2 CARD15 gene, which is associated with certain disease patterns in Crohn's disease.

Crohn's has a genetic component.^[48] Because of this, siblings of known people with Crohn's are 30 times more likely to develop Crohn's than the general population.

The first mutation found to be associated with Crohn's was a frameshift in the NOD2 gene (also known as the CARD15 gene),^[49] followed by the discovery of point mutations.^[50] Over thirty genes have been associated with Crohn's; a biological function is known for most of them. For example, one association is with mutations in the XBP1 gene, which is involved in the unfolded protein response pathway of the endoplasmatic reticulum.^[51]^[52] There is considerable overlap between susceptibility loci for IBD and mycobacterial infections.^[53]

Immune system

There was a prevailing view that Crohn's disease is a primary T cell autoimmune disorder, however a newer theory hypothesizes that Crohn's results from an impaired innate immunity.^[54] The later hypothesis describes impaired cytokine secretion by macrophages, which contributes to impaired innate immunity and leads to a sustained microbial-induced inflammatory response in the colon, where the bacterial load is high.^[4]^[46] Another theory is that the inflammation of Crohn's was caused by an overactive T_h1 cytokine response.^[55] More recent^[when?] studies argue that T_h17 is more important.^[56]

The most recent (2007) gene to be implicated in Crohn's disease is ATG16L1, which may induce autophagy and hinder the body's ability to attack invasive bacteria.^[57] Another recent study has theorized that the human immune system traditionally evolved with the presence of parasites inside the body, and that the lack thereof due to modern hygiene standards has weakened the immune system. Test subjects were reintroduced to harmless parasites, with positive response.^[58]

Microbes

Current thinking is that microorganisms are taking advantage of their host's weakened mucosal layer and inability to clear bacteria from the intestinal walls, which are both symptoms of Crohn's.^[59] Different strains found in tissue and different outcomes to antibiotics therapy and resistance suggest Crohn's Disease is not one disease, but an umbrella of diseases related to different pathogens.^[60]^[61]

A number of studies have suggested a causal role for Mycobacterium avium subspecies paratuberculosis (MAP), which causes a similar disease, Johne's disease, in cattle.^[62]^[63]

NOD2, a gene involved in Crohn's genetic susceptibility, is associated with diminished killing of MAP by macrophages, reduced innate and adaptive immunity in the host and impaired immune responses required for control of intracellular mycobacterial infection.^[64] Macrophages infected with viable MAP are associated with high production of TNF-α.^[65]^[66]

Other studies have linked specific strains of enteroadherent E. coli to the disease.^[67] Adherent-invasive Escherichia coli (AIEC), are more common in people with CD,^[68]^[69]^[70] have the ability to make strong biofilms compared to non-AIEC strains correlating with high adhesion and invasion indices^[71]^[72] of neutrophils and the ability to block autophagy at the autolysosomal step, which allows for intracellular survival of the bacteria and induction of inflammation.^[73] Inflammation drives the proliferation of AIEC and dysbiosis in the ileum, irrespective of genotype.^[74] AIEC strains replicate extensively into macrophages inducing the secretion of very large amounts of TNF-α.^[75]

Mouse studies have suggested some symptoms of Crohn's disease, ulcerative colitis and irritable bowel syndrome have the same underlying cause. Biopsy samples taken from the colons of all three patient groups were found to produce elevated levels of a serine protease.^[76] Experimental introduction of the serine protease into mice has been found to produce widespread pain associated with irritable bowel syndrome, as well as colitis, which is associated with all three diseases.^[77] Regional and temporal variations in those illnesses follow those associated with infection with the protozoan Blastocystis.^[78]

The "cold-chain" hypothesis is that psychrotrophic bacteria such as Yersinia and Listeria species contribute to the disease. A statistical correlation was found between the advent of the use of refrigeration in the United States and various parts of Europe and the rise of the disease.^[79]^[80]^[81]

There is an apparent connection between Crohn's disease, Mycobacterium, other pathogenic bacteria, and genetic markers.^[82]^[83] In many individuals, genetic factors predispose individuals to Mycobacterium avium subsp. paratuberculosis infection. This bacterium then produces mannins, which protect both itself and various bacteria from phagocytosis, which causes a variety of secondary infections.^[84]

Still, this relationship between specific types of bacteria and Crohn's disease remains unclear.^[85]^[86]

Environmental factors

The increased incidence of Crohn's in the industrialized world indicates an environmental component. Crohn's is associated with an increased intake of animal protein, milk protein and an increased ratio of omega-6 to omega-3 polyunsaturated fatty acids.^[87] Those who consume vegetable proteins appear to have a lower incidence of Crohn's disease. Consumption of fish protein has no association.^[87] Smoking increases the risk of the return of active disease (flares).^[11] The introduction of hormonal contraception in the United States in the 1960s is associated with a dramatic increase in incidence, and one hypothesis is that these drugs work on the digestive system in ways similar to smoking.^[88] Isotretinoin is associated with Crohn's.^[89]^[90]^[91] Although stress is sometimes claimed to exacerbate Crohn's disease, there is no concrete evidence to support such claim.^[92] Dietary microparticles, such as those found in toothpaste, have been studied as they produce effects on immunity, but they were not consumed in greater amounts in patients with Crohn's.^[93]^[94]

Pathophysiology

Pathophysiology
[ v t e ]	Crohn's disease	Ulcerative colitis
Cytokine response	Associated with T_h17^[56]	Vaguely associated with T_h2

During a colonoscopy, biopsies of the colon are often taken to confirm the diagnosis. Certain characteristic features of the pathology seen point toward Crohn's disease; it shows a transmural pattern of inflammation, meaning the inflammation may span the entire depth of the intestinal wall.^[1] Ulceration is an outcome seen in highly active disease. There is usually an abrupt transition between unaffected tissue and the ulcer - a characteristic sign known as skip lesions. Under a microscope, biopsies of the affected colon may show mucosal inflammation, characterized by focal infiltration of neutrophils, a type of inflammatory cell, into the epithelium. This typically occurs in the area overlying lymphoid aggregates. These neutrophils, along with mononuclear cells, may infiltrate the crypts, leading to inflammation (crypititis) or abscess (crypt abscess). Granulomas, aggregates of macrophage derivatives known as giant cells, are found in 50% of cases and are most specific for Crohn's disease. The granulomas of Crohn's disease do not show "caseation", a cheese-like appearance on microscopic examination characteristic of granulomas associated with infections, such as tuberculosis. Biopsies may also show chronic mucosal damage, as evidenced by blunting of the intestinal villi, atypical branching of the crypts, and a change in the tissue type (metaplasia). One example of such metaplasia, Paneth cell metaplasia, involves development of Paneth cells (typically found in the small intestine and a key regulator of intestinal microbiota) in other parts of the gastrointestinal system.^[95]^[96]

Diagnosis

The diagnosis of Crohn's disease can sometimes be challenging,^[20] and a number of tests are often required to assist the physician in making the diagnosis.^[23] Even with a full battery of tests, it may not be possible to diagnose Crohn's with complete certainty; a colonoscopy is approximately 70% effective in diagnosing the disease, with further tests being less effective. Disease in the small bowel is particularly difficult to diagnose, as a traditional colonoscopy allows access to only the colon and lower portions of the small intestines; introduction of the capsule endoscopy^[97] aids in endoscopic diagnosis. Multinucleated giant cells, a common finding in the lesions of Crohn's disease, are less common in the lesions of lichen nitidus.^[98]

Endoscopic image of Crohn's colitis showing deep ulceration
CT scan showing Crohn's disease in the fundus of the stomach
This endoscopic image of Crohn's colitis showing diffuse loss of mucosal architecture, friability and exudate
Endoscopic biopsy showing granulomatous inflammation of the colon in a case of Crohn's disease.
Section of colectomy showing transmural inflammation

Classification

Distribution of gastrointestinal Crohn's disease.

Crohn's disease is one type of inflammatory bowel disease (IBD). It typically manifests in the gastrointestinal tract and can be categorized by the specific tract region affected. A disease of both the ileum (the last part of the small intestine that connects to the large intestine), and the large intestine, Ileocolic Crohn's accounts for fifty percent of cases. Crohn's ileitis, manifest in the ileum only, accounts for thirty percent of cases, while Crohn's colitis, of the large intestine, accounts for the remaining twenty percent of cases and may be particularly difficult to distinguish from ulcerative colitis. Gastroduodenal Crohn's disease causes inflammation in the stomach and first part of the small intestine, called the duodenum. Jejunoileitis causes spotty patches of inflammation in the top half of the small intestine, called the jejunum.^{[citation needed]} The disease can attack any part of the digestive tract, from mouth to anus. However, individuals affected by the disease rarely fall outside these three classifications, with presentations in other areas.^[1]

Crohn's disease may also be categorized by the behavior of disease as it progresses. These categorizations formalized in the Vienna classification of the disease.^[99] There are three categories of disease presentation in Crohn's disease: stricturing, penetrating, and inflammatory. Stricturing disease causes narrowing of the bowel that may lead to bowel obstruction or changes in the caliber of the feces. Penetrating disease creates abnormal passageways (fistulae) between the bowel and other structures, such as the skin. Inflammatory disease (or nonstricturing, nonpenetrating disease) causes inflammation without causing strictures or fistulae.^[99]^[100]

Endoscopy

A colonoscopy is the best test for making the diagnosis of Crohn's disease, as it allows direct visualization of the colon and the terminal ileum, identifying the pattern of disease involvement. On occasion, the colonoscope can travel past the terminal ileum, but it varies from person to person. During the procedure, the gastroenterologist can also perform a biopsy, taking small samples of tissue for laboratory analysis, which may help confirm a diagnosis. As 30% of Crohn's disease involves only the ileum,^[1] cannulation of the terminal ileum is required in making the diagnosis. Finding a patchy distribution of disease, with involvement of the colon or ileum, but not the rectum, is suggestive of Crohn's disease, as are other endoscopic stigmata.^[101] The utility of capsule endoscopy for this, however, is still uncertain.^[102] A "cobblestone"-like appearance is seen in approximately 40% of cases of Crohn's disease upon colonoscopy, representing areas of ulceration separated by narrow areas of healthy tissue.

Radiologic tests

A small bowel follow-through may suggest the diagnosis of Crohn's disease and is useful when the disease involves only the small intestine. Because colonoscopy and gastroscopy allow direct visualization of only the terminal ileum and beginning of the duodenum, they cannot be used to evaluate the remainder of the small intestine. As a result, a barium follow-through X-ray, wherein barium sulfate suspension is ingested and fluoroscopic images of the bowel are taken over time, is useful for looking for inflammation and narrowing of the small bowel.^[101]^[103] Barium enemas, in which barium is inserted into the rectum and fluoroscopy is used to image the bowel, are rarely used in the work-up of Crohn's disease due to the advent of colonoscopy. They remain useful for identifying anatomical abnormalities when strictures of the colon are too small for a colonoscope to pass through, or in the detection of colonic fistulae (in this case contrast should be performed with iodate substances).^[104]

CT and MRI scans are useful for evaluating the small bowel with enteroclysis protocols.^[105] They are also useful for looking for intra-abdominal complications of Crohn's disease, such as abscesses, small bowel obstructions, or fistulae.^[106] Magnetic resonance imaging (MRI) is another option for imaging the small bowel as well as looking for complications, though it is more expensive and less readily available^[107]

Blood tests

A complete blood count may reveal anemia, which commonly is caused by blood loss leading to iron deficiency (a microcytic anemia) or by vitamin B₁₂ deficiency (a macrocytic anemia), usually caused by ileal disease impairing vitamin B₁₂ absorption. Rarely autoimmune hemolysis may occur.^[108] Ferritin levels help assess if iron deficiency is contributing to the anemia. Erythrocyte sedimentation rate (ESR) and C-reactive protein help assess the degree of inflammation, which is important as ferritin can also be raised in inflammation.^[109] Serum iron, total iron binding capacity and transferrin saturation may be more easily interpreted in inflammation. Anemia of chronic disease results in a normocytic anemia. Other causes of anemia include medication used in treatment of inflammatory bowel disease, like azathioprine, which can lead to cytopenia, and sulfasalazine, which can also result in folate deficiency. Testing for Saccharomyces cerevisiae antibodies (ASCA) and antineutrophil cytoplasmic antibodies (ANCA) has been evaluated to identify inflammatory diseases of the intestine^[110] and to differentiate Crohn's disease from ulcerative colitis.^[111] Furthermore, increasing amounts and levels of serological antibodies such as ASCA, antilaminaribioside [Glc(β1,3)Glb(β); ALCA], antichitobioside [GlcNAc(β1,4)GlcNAc(β); ACCA], antimannobioside [Man(α1,3)Man(α)AMCA], antiLaminarin [(Glc(β1,3))3n(Glc(β1,6))n; anti-L] and antichitin [GlcNAc(β1,4)n; anti-C] associate with disease behavior and surgery, and may aid in the prognosis of Crohn's disease.^[112]^[113]^[114]^[115]

Comparison with ulcerative colitis

The most common disease that mimics the symptoms of Crohn's disease is ulcerative colitis, as both are inflammatory bowel diseases that can affect the colon with similar symptoms. It is important to differentiate these diseases, since the course of the diseases and treatments may be different. In some cases, however, it may not be possible to tell the difference, in which case the disease is classified as indeterminate colitis.^[1]^[23]^[24]

Diagnostic findings
Sign [ v t e ]	Crohn's disease	Ulcerative colitis
Terminal ileum involvement	Commonly	Seldom
Colon involvement	Usually	Always
Rectum involvement	Seldom	Usually^[41]
Involvement around the anus	Common^[19]	Seldom
Bile duct involvement	No increase in rate of primary sclerosing cholangitis	Higher rate^[116]
Distribution of Disease	Patchy areas of inflammation (Skip lesions)	Continuous area of inflammation^[41]
Endoscopy	Deep geographic and serpiginous (snake-like) ulcers	Continuous ulcer
Depth of inflammation	May be transmural, deep into tissues^[117]^[19]	Shallow, mucosal
Stenosis	Common	Seldom
Granulomas on biopsy	May have non-necrotizing non-peri-intestinal crypt granulomas^[19]^[118]^[119]	Non-peri-intestinal crypt granulomas not seen^[41]

Management

Management
[ v t e ]	Crohn's disease	Ulcerative colitis
Mesalazine	Less useful^[120]	More useful^[120]
Antibiotics	Effective in long-term^[121]	Generally not useful^[122]
Surgery	Often returns following removal of affected part	Usually cured by removal of colon

There is no cure for Crohn's disease and remission may not be possible or prolonged if achieved. In cases where remission is possible, relapse can be prevented and symptoms controlled with medication, lifestyle and dietary changes, changes to eating habits (eating smaller amounts more often), reduction of stress, moderate activity and exercise. Surgery is generally contraindicated and has not been shown to prevent remission. Adequately controlled, Crohn's disease may not significantly restrict daily living.^[123] Treatment for Crohn's disease is only when symptoms are active and involve first treating the acute problem, then maintaining remission.

Lifestyle changes

Certain lifestyle changes can reduce symptoms, including dietary adjustments, elemental diet, proper hydration, and smoking cessation. Smoking may increase Crohn's disease; stopping is recommended. Eating small meals frequently instead of big meals may also help with a low appetite. To manage symptoms have a balanced diet with proper portion control. Fatigue can be helped with regular exercise, a healthy diet, and enough sleep. A food diary may help with identifying foods that trigger symptoms. Some people should follow a low dietary fiber diet to control symptoms especially if fibrous foods cause symptoms.^[123] Some find relief in eliminating casein (protein found in cow's milk) and gluten (protein found in wheat, rye and barley) from their diets. They may have specific dietary intolerances (not allergies).^[124]

Medication

Acute treatment uses medications to treat any infection (normally antibiotics) and to reduce inflammation (normally aminosalicylate anti-inflammatory drugs and corticosteroids). When symptoms are in remission, treatment enters maintenance, with a goal of avoiding the recurrence of symptoms. Prolonged use of corticosteroids has significant side-effects; as a result, they are, in general, not used for long-term treatment. Alternatives include aminosalicylates alone, though only a minority are able to maintain the treatment, and many require immunosuppressive drugs.^[19] It has been also suggested that antibiotics change the enteric flora, and their continuous use may pose the risk of overgrowth with pathogens such as Clostridium difficile.^[125]

Medications used to treat the symptoms of Crohn's disease include 5-aminosalicylic acid (5-ASA) formulations, prednisone, immunomodulators such as azathioprine (given as the prodrug for 6-mercaptopurine), methotrexate, infliximab, adalimumab,^[24] certolizumab^[126] and natalizumab.^[127]^[128] Hydrocortisone should be used in severe attacks of Crohn's disease.^[129]

The gradual loss of blood from the gastrointestinal tract, as well as chronic inflammation, often leads to anemia, and professional guidelines suggest routinely monitoring for this.^[130]^[131]^[132] Adequate disease control usually improves anemia of chronic disease, but iron deficiency may require treatment with iron supplements. Guidelines vary as to how iron should be administered. Some^[132] advise parenteral iron as first line as it works faster, has fewer gastrointestinal side effects, and is unaffected by inflammation reducing enteral absorption.

Other guidelines^[131] advise oral iron as first line with parenteral iron reserved for those that fail to adequately respond as oral iron is considerably cheaper. All agree that severe anemia (hemoglobin under 10g/dL) should be treated with parenteral iron. Blood transfusion should be reserved for those who are cardiovascularly unstable, due the relatively poor safety profile, lack of long term efficacy, and cost.^[131]

Surgery

Crohn's cannot be cured by surgery, though it is used in the case of partial or full blockage of the intestine. Surgery may also be required for complications such as obstructions, fistulas, or abscesses, or if the disease does not respond to drugs. After the first surgery, Crohn's usually shows up at the site of the resection, however it can appear in other locations. After a resection, scar tissue builds up, which can cause strictures, which form when the intestines become too small to allow excrement to pass through easily, which can lead to a blockage. After the first resection, another resection may be necessary within five years.^[133] For patients with an obstruction due to a stricture, two options for treatment are strictureplasty and resection of that portion of bowel. There is no statistical significance between strictureplasty alone versus strictureplasty and resection in cases of duodenal involvement. In these cases, re-operation rates were 31% and 27%, respectively, indicating that strictureplasty is a safe and effective treatment for selected people with duodenal involvement.^[134]

Postsurgical recurrence of Crohn's disease is relatively common. Crohn's lesions are often found at the site of the resected bowel. The join (or anastomosis) after surgery may be inspected, usually during a colonoscopy, and disease activity graded. The "Rutgeert's score" is an endoscopic scoring system for post-operative disease recurrence in Crohn's disease.^[135] Fewer lesions result in a lower grade. Based on the score, treatment plans can be designed to give the patient the best chance of managing recurrence of the disease.^[136]

Short bowel syndrome (SBS, also short gut syndrome or simply short gut) is caused by the surgical removal of part of the small intestine. It usually develops in those patients who have had half or more of their small intestines removed.^[137] Diarrhea is the main symptom, but others may include weight loss, cramping, bloating, and heartburn. Short bowel syndrome is treated with changes in diet, intravenous feeding, vitamin and mineral supplements, and treatment with medications.

Bile acid diarrhea is another complication following surgery for Crohn's disease in which the terminal ileum has been removed. This leads to the development of excessive watery diarrhea. It is usually thought to be due to an inability of the ileum to reabsorb bile acids after resection of the terminal ileum and was the first type of bile acid malabsorption recognized.^[138]

In some cases of SBS, intestinal transplant surgery may be considered; though the number of transplant centres offering this procedure is quite small and it comes with a high risk due to the chance of infection and rejection of the transplanted intestine.^[139]

Alternative medicine

More than half of people with Crohn's disease have tried complementary or alternative therapy.^[140] These include diets, probiotics, fish oil and other herbal and nutritional supplements. Some scientists have suggested more research into these is needed to discriminate between effective therapies and "pseudo" therapies that can be ineffective.^[141]

Acupuncture is used to treat inflammatory bowel disease in China, and is being used more frequently in Western society.^[142] There is insufficient evidence to recommend the use of acupuncture.^[143] Acupuncture also increases the risk of infection.^[144]
Homeopathy is frequently used in Germany as a treatment for Crohn's disease, though no clinical trials exist that demonstrate homeopathy is effective.^[145]

Prognosis

Crohn's disease is a chronic condition for which there is no cure. It is characterised by periods of improvement followed by episodes when symptoms flare up. With treatment, most people achieve a healthy weight, and the mortality rate for the disease is relatively low. It can vary from being benign to very severe and people with CD could experience just one episode or have continuous symptoms. It usually reoccurs, although some people can remain disease free for years or decades. Most people with Crohn's live a normal lifespan.^[146] However, Crohn's disease is associated with a small increase in risk of small bowel and colorectal carcinoma (bowel cancer).^[147]

Complications
[ v t e ]		Crohn's disease	Ulcerative colitis
Nutrient deficiency		Higher risk
Colon cancer risk		Slight	Considerable
Prevalence of extraintestinal complications^[148]
Iritis/uveitis	Females	2.2%	3.2%
Iritis/uveitis	Males	1.3%	0.9%
Primary sclerosing cholangitis	Females	0.3%	1%
Primary sclerosing cholangitis	Males	0.4%	3%
Ankylosing spondylitis	Females	0.7%	0.8%
Ankylosing spondylitis	Males	2.7%	1.5%
Pyoderma gangrenosum	Females	1.2%	0.8%
Pyoderma gangrenosum	Males	1.3%	0.7%
Erythema nodosum	Females	1.9%	2%
Erythema nodosum	Males	0.6%	0.7%

Complications

Crohn's disease can lead to several mechanical complications within the intestines, including obstruction, fistulae, and abscesses.

Obstruction typically occurs from strictures or adhesions that narrow the lumen, blocking the passage of the intestinal contents.

Fistulae can develop between two loops of bowel, between the bowel and bladder, between the bowel and vagina, and between the bowel and skin.

Abscesses are walled off collections of infection, which can occur in the abdomen or in the perianal area.

Crohn's is responsible for 10% of vesicoenteric fistulae, and is the most common cause of ileovesical fistulae.^[149]

Endoscopic image of colon cancer identified in the sigmoid colon on screening colonoscopy for Crohn's disease

Crohn's disease also increases the risk of cancer in the area of inflammation. For example, individuals with Crohn's disease involving the small bowel are at higher risk for small intestinal cancer. Similarly, people with Crohn's colitis have a relative risk of 5.6 for developing colon cancer.^[150] Screening for colon cancer with colonoscopy is recommended for anyone who has had Crohn's colitis for at least eight years.^[151] Some studies suggest there is a role for chemoprotection in the prevention of colorectal cancer in Crohn's involving the colon; two agents have been suggested, folate and mesalamine preparations.^[152]

Individuals with Crohn's disease are at risk of malnutrition for many reasons, including decreased food intake and malabsorption. The risk increases following resection of the small bowel. Such individuals may require oral supplements to increase their caloric intake, or in severe cases, total parenteral nutrition (TPN). Most people with moderate or severe Crohn's disease are referred to a dietitian for assistance in nutrition.^[153]

The major significant complications of Crohn's disease, including bowel obstruction, abscesses, free perforation and hemorrhage,^[154] in rare cases,^[155] may be fatal.^[156]

Crohn's disease can be problematic during pregnancy, and some medications can cause adverse outcomes for the fetus or mother. Consultation with an obstetrician and gastroenterologist about Crohn's disease and all medications facilitates preventative measures. In some cases, remission occurs during pregnancy. Certain medications can also lower sperm count or otherwise adversely affect a man's fertility.^[157]

Epidemiology

The percentage of people with Crohn's disease has been determined in Norway and the United States and is similar at 6 to 7.1:100,000. The Crohn's and Colitis Foundation of America cites this number as approx 149:100,000; NIH cites 28 to 199 per 100,000.^[158]^[159] Crohn's disease is more common in northern countries, and with higher rates still in the northern areas of these country.^[160] The incidence of Crohn's disease is thought to be similar in Europe but lower in Asia and Africa.^[158] It also has a higher incidence in Ashkenazi Jews^[1]^[161] and smokers.^[162]

Crohn's disease begins most commonly in people in their teens and 20s, and people in their 50s through to their 70s.^[1]^[23] It is rarely diagnosed in early childhood. It usually affects females children more severely than males.^[163] However, only slightly more women than men have Crohn's disease.^[164] Parents, siblings or children of people with Crohn's disease are 3 to 20 times more likely to develop the disease.^[165] Twin studies find that if one has the disease there is a 55% chance the other will too.^[166]

History

Inflammatory bowel diseases were described by Giovanni Battista Morgagni (1682–1771) and by Scottish physician T. Kennedy Dalziel in 1913.^[167]

Ileitis terminalis was first described by Polish surgeon Antoni Leśniowski in 1904, however, due to the precedence of Crohn's name in the alphabet, it later became known in the worldwide literature as Crohn's disease.^{[citation needed]} Only in Poland is it still called Leśniowski-Crohn's disease. Burrill Bernard Crohn, an American gastroenterologist at New York City's Mount Sinai Hospital, described fourteen cases in 1932, and submitted them to the American Medical Association under the rubric of "Terminal ileitis: A new clinical entity". Later that year, he, along with colleagues Leon Ginzburg and Gordon Oppenheimer published the case series as "Regional ileitis: a pathologic and clinical entity".^[17]

Research

Some evidence supports the hypothesis that the bacterium Mycobacterium avium subspecies paratuberculosis (MAP) is a cause of Crohn’s disease. As a result, researchers are looking at the eradication of MAP as a therapeutic option.^[168] Treating MAP using antibiotics has been examined and the results are unclear but tentatively beneficial.^[169]^[170] Vaccination against MAP is also being studied. An anti-MAP vaccine appears effective in mice and cattle with MAP with no apparent side effects.^[168]^[171] Trials in human are pending.

Recent studies using helminthic therapy or hookworms to treat Crohn's Disease and other (non-viral) auto-immune diseases seem to yield promising results.^[172]

Numerous preclinical studies demonstrate that activation of the CB1 and CB2 cannabinoid receptors exert biological functions on the gastrointestinal tract.^[173] Activation of CB1 and CB2 receptors in animals has shown a strong anti-inflammatory effect.^[174] Cannabinoids and/or modulation of the endocannabinoid system is a novel therapeutic means for the treatment of numerous GI disorders, including inflammatory bowel diseases like Crohn's disease.^[175]

There is no good evidence that thalidomide or lenalidomide is useful to bring about or maintain remission.^[176]^[177]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r ^s Baumgart DC, Sandborn WJ (2012). "Crohn's disease". The Lancet 380 (9853): 1590–605. doi:10.1016/S0140-6736(12)60026-9. PMID 22914295.
^ ^a ^b ^c ^d "Crohn's Disease". National Digestive Diseases Information Clearinghouse (NDDIC). July 10, 2013. Retrieved 12 June 2014.
^ Cho JH, Brant SR (2011). "Recent Insights into the Genetics of Inflammatory Bowel Disease". Gastroenterology 140 (6): 1704–12. doi:10.1053/j.gastro.2011.02.046. PMID 21530736.
^ ^a ^b ^c Dessein R, Chamaillard M, Danese S (2008). "Innate Immunity in Crohnʼs Disease". Journal of Clinical Gastroenterology 42: S144–7. doi:10.1097/MCG.0b013e3181662c90. PMID 18806708.
^ Stefanelli T, Malesci A, Repici A, Vetrano S, Danese S (2008). "New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets". Current Drug Targets 9 (5): 413–8. doi:10.2174/138945008784221170. PMID 18473770.
^ ^a ^b Marks DJ, Rahman FZ, Sewell GW, Segal AW (2010). "Crohn's disease: An immune deficiency state". Clinical reviews in allergy & immunology 38 (1): 20–31. doi:10.1007/s12016-009-8133-2. PMID 19437144.
^ Casanova JL, Abel L (Aug 31, 2009). "Revisiting Crohn's disease as a primary immunodeficiency of macrophages.". The Journal of experimental medicine 206 (9): 1839–43. doi:10.1084/jem.20091683. PMID 19687225.
^ Lalande JD, Behr MA (2010). "Mycobacteria in Crohn's disease: How innate immune deficiency may result in chronic inflammation". Expert review of clinical immunology 6 (4): 633–41. doi:10.1586/eci.10.29. PMID 20594136.
^ Yamamoto-Furusho JK, Korzenik JR (2006). "Crohn's disease: Innate immunodeficiency?". World Journal of Gastroenterology 12 (42): 6751–5. PMID 17106921.
^ Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ (2008). "Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease". Nature Genetics 40 (8): 955–62. doi:10.1038/ng.175. PMC 2574810. PMID 18587394.
^ ^a ^b Cosnes J (2004). "Tobacco and IBD: Relevance in the understanding of disease mechanisms and clinical practice". Best Practice & Research Clinical Gastroenterology 18 (3): 481–96. doi:10.1016/j.bpg.2003.12.003. PMID 15157822.
^ Molodecky, NA; Soon, IS; Rabi, DM; Ghali, WA; Ferris, M; Chernoff, G; Benchimol, EI; Panaccione, R; Ghosh, S; Barkema, HW; Kaplan, GG (Jan 2012). "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.". Gastroenterology 142 (1): 46–54.e42; quiz e30. doi:10.1053/j.gastro.2011.10.001. PMID 22001864.
^ Prideaux, L; Kamm, MA; De Cruz, PP; Chan, FK; Ng, SC (Aug 2012). "Inflammatory bowel disease in Asia: a systematic review.". Journal of Gastroenterology and Hepatology 27 (8): 1266–80. doi:10.1111/j.1440-1746.2012.07150.x. PMID 22497584.
^ ^a ^b Hovde, Ø; Moum, BA (Apr 21, 2012). "Epidemiology and clinical course of Crohn's disease: results from observational studies.". World journal of gastroenterology : WJG 18 (15): 1723–31. doi:10.3748/wjg.v18.i15.1723. PMC 3332285. PMID 22553396.
^ ^a ^b Burisch, J; Munkholm, P (Jul 2013). "Inflammatory bowel disease epidemiology.". Current opinion in gastroenterology 29 (4): 357–62. doi:10.1097/MOG.0b013e32836229fb. PMID 23695429.
^ Lozano, R; Naghavi, M (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.". Lancet 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604.
^ ^a ^b Crohn BB, Ginzburg L, Oppenheimer GD (2000). "Regional ileitis: A pathologic and clinical entity. 1932". The Mount Sinai journal of medicine, New York 67 (3): 263–8. PMID 10828911.
^ ^a ^b ^c ^d ^e ^f internetmedicin.se > Inflammatorisk tarmsjukdom, kronisk, IBD By Robert Löfberg. Retrieved Oct 2010 Translate.
^ ^a ^b ^c ^d ^e Hanauer SB, Sandborn W (2001-03-01). "Management of Crohn's disease in adults" (PDF). American Journal of Gastroenterology 96 (3): 635–43. doi:10.1111/j.1572-0241.2001.03671.x. PMID 11280528. Retrieved 2009-11-07.
^ ^a ^b Pimentel M, Chang M, Chow EJ, Tabibzadeh S, Kirit-Kiriak V, Targan SR, Lin HC (2000). "Identification of a prodromal period in Crohn's disease but not ulcerative colitis". The American Journal of Gastroenterology 95 (12): 3458–62. doi:10.1111/j.1572-0241.2000.03361.x. PMID 11151877.
^ Crohn's Disease Overview
^ ^a ^b Zieve, David; George F Longstreth (October 18, 2009). "Crohn's Disease". ADAM Health Illustrated Encyclopedia. Retrieved 2010-08-16. ^{[verification needed]}
^ ^a ^b ^c ^d ^e ^f ^g Crohn Disease at eMedicine
^ ^a ^b ^c Podolsky DK (2002). "Inflammatory Bowel Disease". New England Journal of Medicine 347 (6): 417–29. doi:10.1056/NEJMra020831. PMID 12167685.
^ Mueller MH, Kreis ME, Gross ML, Becker HD, Zittel TT, Jehle EC (2002). "Anorectal functional disorders in the absence of anorectal inflammation in patients with Crohn's disease". British Journal of Surgery 89 (8): 1027–31. doi:10.1046/j.1365-2168.2002.02173.x. PMID 12153630.
^ Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (July 30, 2004). "The Gastrointestinal Tract". Robbins and Cotran: Pathologic Basis of Disease (7th ed.). Philadelphia, Pennsylvania: Elsevier Saunders. p. 847. ISBN 0-7216-0187-1.
^ Taylor BA, Williams GT, Hughes LE, Rhodes J (1989). "The histology of anal skin tags in Crohn's disease: An aid to confirmation of the diagnosis". International Journal of Colorectal Disease 4 (3): 197–9. doi:10.1007/BF01649703. PMID 2769004.
^ Fix OK, Soto JA, Andrews CW, Farraye FA (2004). "Gastroduodenal Crohn's disease". Gastrointestinal Endoscopy 60 (6): 985. doi:10.1016/S0016-5107(04)02200-X. PMID 15605018.
^ ^a ^b Beattie RM, Croft NM, Fell JM, Afzal NA, Heuschkel RB (2006). "Inflammatory bowel disease". Archives of Disease in Childhood 91 (5): 426–32. doi:10.1136/adc.2005.080481. PMC 2082730. PMID 16632672.
^ Büller HA (1997). "Problems in diagnosis of IBD in children". The Netherlands Journal of Medicine 50 (2): S8–11. doi:10.1016/S0300-2977(96)00064-2. PMID 9050326.
^ O'Keefe SJ (1996). "Nutrition and gastrointestinal disease". Scand. J. Gastroenterol. Suppl. 220: 52–9. doi:10.3109/00365529609094750. PMID 8898436.
^ Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A (2005). "Extraintestinal manifestations in inflammatory bowel disease". World Journal of Gastroenterology 11 (46): 7227–36. PMID 16437620.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k Trikudanathan G, Venkatesh PG, Navaneethan U (2012). "Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease". Drugs 72 (18): 2333–49. doi:10.2165/11638120-000000000-00000. PMID 23181971.
^ ^a ^b Thrash B, Patel M, Shah KR, Boland CR, Menter A (2013). "Cutaneous manifestations of gastrointestinal disease: part II". Journal of the American Academy of Dermatology 68 (2): 211 e1–33. doi:10.1016/j.jaad.2012.10.036. PMID 23317981.
^ Bernstein M, Irwin S, Greenberg GR (2005). "Maintenance Infliximab Treatment is Associated with Improved Bone Mineral Density in Crohn's Disease". The American Journal of Gastroenterology 100 (9): 2031–5. doi:10.1111/j.1572-0241.2005.50219.x. PMID 16128948.
^ ^a ^b ^c Lomer MC (August 2011). "Dietary and nutritional considerations for inflammatory bowel disease". The Proceedings of the Nutrition Society 70 (3): 329–35. doi:10.1017/S0029665111000097. PMID 21450124.
^ ^a ^b ^c Gerasimidis K, McGrogan P, Edwards CA (August 2011). "The aetiology and impact of malnutrition in paediatric inflammatory bowel disease". Journal of Human Nutrition and Dietetics 24 (4): 313–26. doi:10.1111/j.1365-277X.2011.01171.x. PMID 21564345.
^ ^a ^b Crohn's disease. professionals.epilepsy.com. Retrieved July 13, 2007.
^ MedlinePlus Encyclopedia Small bowel bacterial overgrowth
^ Zadik Y, Drucker S, Pallmon S (2011). "Migratory stomatitis (ectopic geographic tongue) on the floor of the mouth". Journal of the American Academy of Dermatology 65 (2): 459–60. doi:10.1016/j.jaad.2010.04.016. PMID 21763590.
^ ^a ^b ^c ^d Kornbluth A, Sachar DB (July 2004). "Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee". American Journal of Gastroenterology 99 (7): 1371–85. doi:10.1111/j.1572-0241.2004.40036.x. PMID 15233681. Archived from the original on April 6, 2008. Retrieved 2009-11-07.
^ Crohn's Disease Overview
^ "Crohn's diseaseShare on facebookShare on twitterBookmark & SharePrinter-friendly version". 2013-10-13. Retrieved 16 September 2014.
^ Braat H, Peppelenbosch MP, Hommes DW (August 2006). "Immunology of Crohn's disease". Annals of the New York Academy of Sciences 1072: 135–54. doi:10.1196/annals.1326.039. PMID 17057196.
^ Henckaerts L, Figueroa C, Vermeire S, Sans M (May 2008). "The role of genetics in inflammatory bowel disease". Curr Drug Targets 9 (5): 361–8. doi:10.2174/138945008784221161. PMID 18473763.
^ ^a ^b Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW (2006). "Defective acute inflammation in Crohn's disease: a clinical investigation". Lancet 367 (9511): 668–78. doi:10.1016/S0140-6736(06)68265-2. PMID 16503465.
^ Comalada M, Peppelenbosch MP (September 2006). "Impaired innate immunity in Crohn's disease". Trends Mol Med 12 (9): 397–9. doi:10.1016/j.molmed.2006.07.005. PMID 16890491.
^ "Crohn's disease has strong genetic link: study". Crohn's and Colitis Foundation of America. 2007-04-16. Retrieved 2009-11-07.
^ Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH (2001). "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease". Nature 411 (6837): 603–6. doi:10.1038/35079114. PMID 11385577.
^ Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG (2002). "The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease". Gastroenterology 122 (4): 867–74. doi:10.1053/gast.2002.32415. PMID 11910337.
^ Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EE, Higgins DE, Schreiber S, Glimcher LH, Blumberg RS (5 September 2008). "XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease". Cell 134 (5): 743–56. doi:10.1016/j.cell.2008.07.021. PMC 2586148. PMID 18775308.
^ Clevers H (2009). "Inflammatory Bowel Disease, Stress, and the Endoplasmic Reticulum". New England Journal of Medicine 360 (7): 726–27. doi:10.1056/NEJMcibr0809591. PMID 19213688.
^ Jostins L, Ripke S, Weersma RK, et al. (2012). "Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease". Nature 491 (7422): 119–24. doi:10.1038/nature11582. PMC 3491803. PMID 23128233.
^ Marks DJ, Segal AW (January 2008). "Innate immunity in inflammatory bowel disease: a disease hypothesis". J Pathol. 214 (2): 260–6. doi:10.1002/path.2291. PMC 2635948. PMID 18161747.
^ Cobrin GM, Abreu MT (2005). "Defects in mucosal immunity leading to Crohn's disease". Immunol. Rev. 206: 277–95. doi:10.1111/j.0105-2896.2005.00293.x. PMID 16048555.
^ ^a ^b Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA (2007). "Monoclonal Anti – Interleukin 23 Reverses Active Colitis in a T Cell – Mediated Model in Mice". Gastroenterology 132 (7): 2359–70. doi:10.1053/j.gastro.2007.03.104. PMID 17570211.
^ Prescott NJ, Fisher SA, Franke A, Hampe J, Onnie CM, Soars D, Bagnall R, Mirza MM, Sanderson J, Forbes A, Mansfield JC, Lewis CM, Schreiber S, Mathew CG (2007). "A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5". Gastroenterology 132 (5): 1665–71. doi:10.1053/j.gastro.2007.03.034. PMID 17484864.
^ Moises Velasquez-Manoff (June 29, 2008). "The Worm Turns". The New York Times.
^ Sartor, R Balfour (2006). "Mechanisms of Disease: Pathogenesis of Crohn's disease and ulcerative colitis". Nature Clinical Practice Gastroenterology & Hepatology 3 (7): 390. doi:10.1038/ncpgasthep0528.
^ Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang ZD, Dupont HL, Garneau P, Harel J, Rishniw M, Simpson KW (2013). "Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease". Inflamm. Bowel Dis. 19 (1): 141–50. doi:10.1002/ibd.22971. PMID 22508665.
^ http://www.scirp.org/journal/PaperInformation.aspx?paperID=19619 The many faces of Crohn's Disease: Latest concepts in etiology
^ Naser SA, Collins MT (December 2005). "Debate on the lack of evidence of Mycobacterium avium subsp. paratuberculosis in Crohn's disease". Inflamm. Bowel Dis. 11 (12): 1123. doi:10.1097/01.MIB.0000191609.20713.ea. PMID 16306778.
^ Naser SA, Sagramsingh SR, Naser AS, and Naser ST (June 2014). "Mycobacterium avium subspecies paratuberculosis causes Crohn's disease in some inflammatory bowel disease patients". World J Gastroenterol. 20 (23): 7403–7415. doi:10.3748/wjg.v20.i23.7403. PMC 4064085.
^ Glubb DM, Gearry RB, Barclay ML, Roberts RL, Pearson J, Keenan JI, McKenzie J, Bentley RW (2011). "NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease". World Journal of Gastroenterology 17 (23): 2829–37. doi:10.3748/wjg.v17.i23.2829. PMC 3120942. PMID 21734790.
^ Clancy R, Ren Z, Turton J, Pang G, Wettstein A (2007). "Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion". Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 39 (5): 445–51. doi:10.1016/j.dld.2006.12.006. PMID 17317344.
^ Nakase H, Tamaki H, Matsuura M, Chiba T, Okazaki K (2011). "Involvement of mycobacterium avium subspecies paratuberculosis in TNF-α production from macrophage: Possible link between MAP and immune response in Crohn's disease". Inflammatory bowel diseases 17 (11): E140–2. doi:10.1002/ibd.21750. PMID 21990211.
^ Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW (2007). "Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum". The ISME Journal 1 (5): 403–18. doi:10.1038/ismej.2007.52. PMID 18043660.
^ Sasaki M, Sitaraman SV, Babbin BA, Gerner-Smidt P, Ribot EM, Garrett N, Alpern JA, Akyildiz A, Theiss AL, Nusrat A, Klapproth JM (2007). "Invasive Escherichia coli are a feature of Crohn's disease". Laboratory investigation; a journal of technical methods and pathology 87 (10): 1042–54. doi:10.1038/labinvest.3700661. PMID 17660846.
^ Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF (2004). "High prevalence of Adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease". Gastroenterology 127 (2): 412–21. doi:10.1053/j.gastro.2004.04.061. PMID 15300573.
^ Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW (2007). "Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum". The ISME journal () 1 (5): 403–18. doi:10.1038/ismej.2007.52. PMID 18043660.
^ Nickerson KP, McDonald C (2012). Mizoguchi, Emiko, ed. "Crohn's Disease-Associated Adherent-Invasive Escherichia coli Adhesion is Enhanced by Exposure to the Ubiquitous Dietary Polysaccharide Maltodextrin". PLoS ONE () 7 (12): e52132. doi:10.1371/journal.pone.0052132. PMC 3520894. PMID 23251695.
^ Martinez-Medina M, Naves P, Blanco J, Aldeguer X, Blanco JE, Blanco M, Ponte C, Soriano F, Darfeuille-Michaud A, Garcia-Gil LJ (2009). "Biofilm formation as a novel phenotypic feature of adherent-invasive Escherichia coli (AIEC)". BMC Microbiology 9: 202. doi:10.1186/1471-2180-9-202. PMC 2759958. PMID 19772580.
^ Chargui A, Cesaro A, Mimouna S, Fareh M, Brest P, Naquet P, Darfeuille-Michaud A, Hébuterne X, Mograbi B, Vouret-Craviari V, Hofman P (2012). "Subversion of autophagy in adherent invasive Escherichia coli-infected neutrophils induces inflammation and cell death". PLoS ONE 7 (12): e51727. doi:10.1371/journal.pone.0051727. PMC 3522719. PMID 23272151.
^ Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, Bowman D, Scherl EJ, Simpson KW (2012). "Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease". PLoS ONE 7 (7): e41594. doi:10.1371/journal.pone.0041594. PMC 3404971. PMID 22848538.
^ Barnich N, Darfeuille-Michaud A (January 2007). "Adherent-invasive Escherichia coli and Crohn's disease". Current Opinion in Gastroenterology 23 (1): 16–20. doi:10.1097/MOG.0b013e3280105a38. PMID 17133079.
^ Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N (March 2007). "Role for protease activity in visceral pain in irritable bowel syndrome". J. Clin. Invest. 117 (3): 636–47. doi:10.1172/JCI29255. PMC 1794118. PMID 17304351.
^ Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia-Villar R, Bueno L, Vergnolle N (November 2002). "Induction of Intestinal Inflammation in Mouse by Activation of Proteinase-Activated Receptor-2". Am. J. Pathol. 161 (5): 1903–15. doi:10.1016/S0002-9440(10)64466-5. PMC 1850779. PMID 12414536.
^ Boorom KF, Smith H, Nimri L, Viscogliosi E, Spanakos G, Parkar U, Li LH, Zhou XN, Ok UZ, Leelayoova S, Jones MS (October 2008). "Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection". Parasit Vectors 1 (1): 40. doi:10.1186/1756-3305-1-40. PMC 2627840. PMID 18937874.
^ Hugot JP, Alberti C, Berrebi D, Bingen E, Cézard JP (2003). "Crohn's disease: the cold chain hypothesis". Lancet 362 (9400): 2012–5. doi:10.1016/S0140-6736(03)15024-6. PMID 14683664.
^ "Fridges blamed for Crohn's disease rise". Medical News Today. 2003-12-12.
^ Forbes A, Kalantzis T (2005). "Crohn's disease: The cold chain hypothesis". International Journal of Colorectal Disease 21 (5): 399–401. doi:10.1007/s00384-005-0003-7. PMID 16059694.
^ Subramanian S, Roberts CL, Hart CA, Martin HM, Edwards SW, Rhodes JM, Campbell BJ (2007). "Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics". Antimicrobial Agents and Chemotherapy 52 (2): 427–34. doi:10.1128/AAC.00375-07. PMC 2224732. PMID 18070962.
^ Mpofu CM, Campbell BJ, Subramanian S, Marshall-Clarke S, Hart CA, Cross A, Roberts CL, McGoldrick A, Edwards SW, Rhodes JM (2007). "Microbial Mannan Inhibits Bacterial Killing by Macrophages: A Possible Pathogenic Mechanism for Crohn's Disease". Gastroenterology 133 (5): 1487–98. doi:10.1053/j.gastro.2007.08.004. PMID 17919633.
^ "New insights into Crohn's Disease".
^ "Possible links between Crohn's disease and Paratuberculosis". European Commission Directorate-General Health & Consumer Protection. Retrieved 2009-11-07.
^ Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J (1997). "Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics". Journal of Antimicrobial Chemotherapy 39 (3): 393–400. doi:10.1093/jac/39.3.393. PMID 9096189.
^ ^a ^b Shoda R, Matsueda K, Yamato S, Umeda N (1996). "Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan". The American journal of clinical nutrition 63 (5): 741–5. PMID 8615358.
^ Lesko SM, Kaufman DW, Rosenberg L, Helmrich SP, Miller DR, Stolley PD, Shapiro S (1985). "Evidence for an increased risk of Crohn's disease in oral contraceptive users". Gastroenterology 89 (5): 1046–9. PMID 4043662.
^ Reddy D, Siegel CA, Sands BE, Kane S (July 2006). "Possible association between isotretinoin and inflammatory bowel disease". The American journal of gastroenterology 101 (7): 1569–73. doi:10.1111/j.1572-0241.2006.00632.x. PMID 16863562.
^ Borobio E, Arín A, Valcayo A, Iñarrairaegui M, Nantes O, Prieto C (2004). "[Isotretinoin and ulcerous colitis]". An Sist Sanit Navar (in Spanish; Castilian) 27 (2): 241–3. doi:10.4321/S1137-66272004000300009. PMID 15381956.
^ Reniers DE, Howard JM (October 2001). "Isotretinoin-induced inflammatory bowel disease in an adolescent". Annals of Pharmacotherapy 35 (10): 1214–6. doi:10.1345/aph.10368. PMID 11675849.
^ "Crohn's Disease". National Digestive Diseases Information Clearinghouse. Retrieved 13 November 2012.
^ Lomer MC, Hutchinson C, Volkert S, Greenfield SM, Catterall A, Thompson RP, Powell JJ (December 2004). "Dietary sources of inorganic microparticles and their intake in healthy subjects and patients with Crohn's disease". Br. J. Nutr. 92 (6): 947–55. doi:10.1079/bjn20041276. PMID 15613257.
^ Powell JJ, Thoree V, Pele LC (October 2007). "Dietary microparticles and their impact on tolerance and immune responsiveness of the gastrointestinal tract". Br. J. Nutr. 98 Suppl 1: S59–63. doi:10.1017/S0007114507832922. PMC 2737314. PMID 17922962.
^ Crawford JM. "The Gastrointestinal tract, Chapter 17". In Cotran RS, Kumar V, Robbins SL. Robbins Pathologic Basis of Disease: 5th Edition. W.B. Saunders and Company, Philadelphia, 1994.
^ http://www.plos.org/media/press/2012/PLoS_%20HMP_Collection_Manuscript_Summaries.pdf
^ HCP: Pill Cam, Capsule Endoscopy, Esophageal Endoscopy
^ Scheinfeld NS, Teplitz E, McClain SA (November 2001). "Crohn's disease and lichen nitidus: a case report and comparison of common histopathologic features". Inflammatory Bowel Diseases 7 (4): 314–8. doi:10.1097/00054725-200111000-00006. PMID 11720321.
^ ^a ^b Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR (2007). "A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998". Inflammatory Bowel Diseases 6 (1): 8–15. doi:10.1002/ibd.3780060103. PMID 10701144.
^ Dubinsky MC, Fleshner PP (2003). "Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes". Current Treatment Options in Gastroenterology 6 (3): 183–200. doi:10.1007/s11938-003-0001-1. PMID 12744819.
^ ^a ^b Hara AK, Leighton JA, Heigh RI, Sharma VK, Silva AC, De Petris G, Hentz JG, Fleischer DE (2005). "Crohn Disease of the Small Bowel: Preliminary Comparison among CT Enterography, Capsule Endoscopy, Small-Bowel Follow-through, and Ileoscopy". Radiology 238 (1): 128–34. doi:10.1148/radiol.2381050296. PMID 16373764.
^ Triester SL, Leighton JA, Leontiadis GI, Gurudu SR, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK (2006). "A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease". The American Journal of Gastroenterology 101 (5): 954–64. doi:10.1111/j.1572-0241.2006.00506.x. PMID 16696781.
^ Dixon PM, Roulston ME, Nolan DJ (1993). "The small bowel enema: A ten year review". Clinical Radiology 47 (1): 46–8. doi:10.1016/S0009-9260(05)81213-9. PMID 8428417.
^ Carucci LR, Levine MS (2002). "Radiographic imaging of inflammatory bowel disease". Gastroenterology Clinics of North America 31 (1): 93–117, ix. doi:10.1016/S0889-8553(01)00007-3. PMID 12122746.
^ Rajesh A, Maglinte DD (2006). "Multislice CT enteroclysis: technique and clinical applications". Clinical Radiology 61 (1): 31–9. doi:10.1016/j.crad.2005.08.006. PMID 16356814.
^ Zissin R, Hertz M, Osadchy A, Novis B, Gayer G (2005). "Computed Tomographic Findings of Abdominal Complications of Crohn's Disease—Pictorial Essay" (PDF). Canadian Association of Radiologists Journal 56 (1): 25–35. PMID 15835588. Archived from the original on April 6, 2008. Retrieved 2009-11-07.
^ Mackalski BA, Bernstein CN (2005). "New diagnostic imaging tools for inflammatory bowel disease". Gut 55 (5): 733–41. doi:10.1136/gut.2005.076612. PMC 1856109. PMID 16609136.
^ Goh J, O'Morain CA (2003). "Nutrition and adult inflammatory bowel disease". Alimentary Pharmacology and Therapeutics 17 (3): 307–20. doi:10.1046/j.1365-2036.2003.01482.x. PMID 12562443.
^ Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R (2006). "Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn's Disease". Clinical Gastroenterology and Hepatology 4 (7): 882–7. doi:10.1016/j.cgh.2006.02.003. PMID 16630759.
^ Kaila B, Orr K, Bernstein CN (2005). "The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease". The Canadian Journal of Gastroenterology 19 (12): 717–21. PMID 16341311. Retrieved 2006-07-02.
^ Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y (2005). "Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease". Gut 54 (9): 1232–6. doi:10.1136/gut.2004.060228. PMC 1774672. PMID 16099791.
^ Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S (2007). "New serological markers in inflammatory bowel disease are associated with complicated disease behaviour". Gut 56 (10): 1394–403. doi:10.1136/gut.2006.108043. PMC 2000264. PMID 17456509.
^ Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J, Lakatos PL (2008). "New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort". The American Journal of Gastroenterology 103 (3): 665–81. doi:10.1111/j.1572-0241.2007.01652.x. PMID 18047543.
^ Seow CH, Stempak JM, Xu W, Lan H, Griffiths AM, Greenberg GR, Steinhart AH, Dotan N, Silverberg MS (2009). "Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype". Am J Gastroenterol 104 (6): 1426–34. doi:10.1038/ajg.2009.79. PMID 19491856.
^ Dotan I (2007). "Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification". Expert Rev Gastroenterol Hepatol 1 (2): 265–74. doi:10.1586/17474124.1.2.265. PMID 19072419.
^ Broomé U, Bergquist A (February 2006). "Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer". Seminars in Liver Disease 26 (1): 31–41. doi:10.1055/s-2006-933561. PMID 16496231.
^ Baumgart DC, Sandborn WJ (May 2007). "Inflammatory bowel disease: clinical aspects and established and evolving therapies.". The Lancet 369 (9573): 1641–57. doi:10.1016/S0140-6736(07)60751-X. PMID 17499606. Retrieved 2009-11-04.
^ Shepherd NA (August 2002). "Granulomas in the diagnosis of intestinal Crohn's disease: a myth exploded?". Histopathology 41 (2): 166–8. doi:10.1046/j.1365-2559.2002.01441.x. PMID 12147095.
^ Mahadeva U, Martin JP, Patel NK, Price AB (July 2002). "Granulomatous ulcerative colitis: a re-appraisal of the mucosal granuloma in the distinction of Crohn's disease from ulcerative colitis". Histopathology 41 (1): 50–5. doi:10.1046/j.1365-2559.2002.01416.x. PMID 12121237.
^ ^a ^b Pages 152-156 (Section: Inflammatory bowel disease(IBD)) in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 0-7817-7153-6.
^ Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M (2010). "Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials". Clin. Infect. Dis. 50 (4): 473–80. doi:10.1086/649923. PMID 20067425.
^ [1] Section "Antibiotics and Ulcerative Colitis" in: Prantera C, Scribano ML (2009). "Antibiotics and probiotics in inflammatory bowel disease: why, when, and how". Curr. Opin. Gastroenterol. 25 (4): 329–33. doi:10.1097/MOG.0b013e32832b20bf. PMID 19444096.
^ ^a ^b Fries, WS; Nazario, B (2007-05-16). "Crohn's Disease: 54 Tips to Help You Manage". WebMD. Retrieved 2008-02-14.
^ Escott-Stump, Sylvia (2008). Nutrition and Diagnosis-Related Care, 7th edition. Baltimore, MD: Lippincott Williams & Wilkins. pp. 1020 (pp 431). ISBN 978-1-60831-017-3.
^ Shanahan, Fergus (1 January 2002). "Crohn's disease". The Lancet 359 (9300): 62–69. doi:10.1016/S0140-6736(02)07284-7.
^ "FDA Approves Cimzia to Treat Crohn's Disease" (Press release). U.S. Food and Drug Administration (FDA). April 22, 2008. Retrieved 2009-11-05.
^ Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P (2005). "Natalizumab Induction and Maintenance Therapy for Crohn's Disease". New England Journal of Medicine 353 (18): 1912–25. doi:10.1056/NEJMoa043335. PMID 16267322.
^ MacDonald JK, McDonald JW (2007). MacDonald, John K, ed. "Natalizumab for induction of remission in Crohn's disease". Cochrane Database of Systematic Reviews (1): CD006097. doi:10.1002/14651858.CD006097.pub2. PMID 17253580. CD006097.
^ Longmore, Murray; Ian Wilkinson; Tom Turmezei; Chee Kay Cheung (2007). Oxford Handbook of Clinicial Medicine (7th ed.). Oxford University Press. pp. 266–7. ISBN 0-19-856837-1.
^ Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S (May 2011). "Guidelines for the management of inflammatory bowel disease in adults". Gut 60 (5): 571–607. doi:10.1136/gut.2010.224154. PMID 21464096.
^ ^a ^b ^c Goddard AF, James MW, McIntyre AS, Scott BB (2011). "Guidelines for the management of iron deficiency anaemia". Gut 60 (10): 1309–1316. doi:10.1136/gut.2010.228874. PMID 21561874.
^ ^a ^b Inflamm Bowel Dis Volume 13, Number 12, December 2007
^ Tresca, AJ (2007-01-12). "Resection Surgery for Crohn's Disease". About.com. Retrieved 2008-02-14.
^ Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA (1996). "Reoperative rates for Crohn's disease following strictureplasty. Long-term analysis". Dis. Colon Rectum 39 (11): 1199–203. doi:10.1007/BF02055108. PMID 8918424.
^ Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M (October 1990). "Predictability of the postoperative course of Crohn's disease". Gastroenterology 99 (4): 956–63. PMID 2394349.
^ Yamamoto T, Bamba T, Umegae S, Matsumoto K (August 2013). "The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn's disease: A 5-year prospective cohort study". United European Gastroenterol J 1 (4): 294–8. doi:10.1177/2050640613495197. PMC 4040796. PMID 24917974.
^ Short Bowel Syndrome as defined by the National Institute of Diabetes and Digestive and Kidney Diseases
^ Hofmann AF (1967). "The syndrome of ileal disease and the broken enterohepatic circulation: cholerhetic enteropathy.". Gastroenterology 52 (4): 752–7. PMID 5337211.
^ Rhodes, M (2006-10-24). "Intestinal transplant for Crohn's disease". Everyday Health. Retrieved 2009-03-22.
^ Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ (2006). "European evidence based consensus on the diagnosis and management of Crohn's disease: special situations". Gut. 55 Suppl 1 (Suppl 1): i36–58. doi:10.1136/gut.2005.081950c. PMC 1859996. PMID 16481630.
^ "Use of complementary and alternative medicine in Germany – a survey of patients with inflammatory bowel disease". BioMed Central. Retrieved 21 September 2010. "At the same time, further clinical studies assessing the most commonly used CAM therapies are urgently needed. Research in CAM offers the chance to discover new treatment options in the management of IBD but may also protect patients from ineffective and expensive 'pseudo'-therapies."
^ Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, Hahn EG, Schuppan D (2004). "Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study". Digestion 69 (3): 131–9. doi:10.1159/000078151. PMID 15114043.
^ Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ (2006). "The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations". Gut 55 (Suppl 1): i36–i58. doi:10.1136/gut.2005.081950c. PMC 1859996. PMID 16481630. "the colitis activity index fell significantly in the treatment group compared to the sham acupuncture group. However, recruitment did not reach its target and the number of patients was small." ^{[verification needed]}
^ Ernst, E.; Lee, Myeong Soo; Choi, Tae-Young (2011). "Acupuncture: Does it alleviate pain and are there serious risks? A review of reviews" (PDF). Pain 152 (4): 755–764. doi:10.1016/j.pain.2010.11.004. ISSN 0304-3959. PMID 21440191.
^ Smart HL, Mayberry JF, Atkinson M (1986). "Alternative medicine consultations and remedies in patients with the irritable bowel syndrome". Gut 27 (7): 826–8. doi:10.1136/gut.27.7.826. PMC 1433575. PMID 3755416.
^ "Crohn's disease - Prognosis". University of Maryland Medical Centre. Retrieved 19 October 2012.
^ Canavan C, Abrams KR, Mayberry J (2006). "Meta-analysis: Colorectal and small bowel cancer risk in patients with Crohn's disease". Alimentary Pharmacology and Therapeutics 23 (8): 1097–104. doi:10.1111/j.1365-2036.2006.02854.x. PMID 16611269.
^ Prevalence defined as at least 5 health care contacts in a 10 year period for the condition, according to: Greenstein AJ, Janowitz HD, Sachar DB (September 1976). "The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients". Medicine (Baltimore) 55 (5): 401–12. doi:10.1097/00005792-197609000-00004. PMID 957999.
^ Enterovesical Fistula at eMedicine
^ Ekbom A, Helmick C, Zack M, Adami HO (1990). "Increased risk of large-bowel cancer in Crohn's disease with colonic involvement". Lancet 336 (8711): 357–9. doi:10.1016/0140-6736(90)91889-I. PMID 1975343.
^ Collins PD, Mpofu C, Watson AJ, Rhodes JM (2006). Watson, Alastair J, ed. "Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease". Cochrane Database Syst Rev (2): CD000279. doi:10.1002/14651858.CD000279.pub3. PMID 16625534.
^ Zisman TL, Rubin DT (2008). "Colorectal cancer and dysplasia in inflammatory bowel disease". World Journal of Gastroenterology 14 (17): 2662–9. doi:10.3748/wjg.14.2662. PMC 2709054. PMID 18461651.
^ Evans JP, Steinhart AH, Cohen Z, McLeod RS (2003). "Home Total Parenteral Nutrition an Alternative to Early Surgery for Complicated Inflammatory Bowel Disease". Journal of Gastrointestinal Surgery 7 (4): 562–6. doi:10.1016/S1091-255X(02)00132-4. PMID 12763417.
^ "Complications of Crohn's Disease". Centocor Ortho Biotech. Retrieved 2009-11-07.
^ Carrillo, Maria (September 1, 1985). "Man of Many Problems Comes to City for Help". Richmond Times-Dispatch (Richmond, Virginia, USA). p. B1.
^ "Kay, Laura Lynn". Richmond Times-Dispatch (Richmond, Virginia, USA). April 3, 2014.
Loebenberg, Priscilla (March 2, 2014). "Doris L. Johnson, 82, of Westminster". Carroll County Times (Westminster, Maryland, USA).
Berrier Jr., Ralph (December 31, 2013). "In memoriam: Dan Hodges Jr.". The Roanoke Times (Roanoke, Virginia, USA).
"Cynthia Meredith Routt". Daily Press (Newport News, Virginia, USA). May 4, 2014. p. A11.
^ Kaplan, C (2005-10-21). "IBD and Pregnancy: What You Need to Know". Crohn's and Colitis Foundation of America. Archived from the original on 2012-02-17. Retrieved 2009-11-07.
^ ^a ^b Hiatt RA, Kaufman L (1988). "Epidemiology of inflammatory bowel disease in a defined northern California population". Western Journal of Medicine 149 (5): 541–6. PMC 1026530. PMID 3250100.
^ Moum B, Vatn MH, Ekbom A, Aadland E, Fausa O, Lygren I, Stray N, Sauar J, Schulz T (1996). "Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists". Scandinavian Journal of Gastroenterology 31 (4): 355–61. doi:10.3109/00365529609006410. PMID 8726303.
^ Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M (1996). "Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)". Gut 39 (5): 690–7. doi:10.1136/gut.39.5.690. PMC 1383393. PMID 9014768.
^ Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI (1993). "Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews". Gut 34 (4): 517–24. doi:10.1136/gut.34.4.517. PMC 1374314. PMID 8491401.
^ Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J (2009). "Effects of light smoking consumption on the clinical course of Crohn's disease". Inflamm. Bowel Dis. 15 (5): 734–41. doi:10.1002/ibd.20828. PMID 19067428.
^ "Crohn's disease manifests differently in boys and girls". Crohn's and Colitis Foundation of America.
^ "Who is affected by Crohn's disease". Healthwise.
^ Satsangi J, Jewell DP, Bell JI (1997). "The genetics of inflammatory bowel disease". Gut 40 (5): 572–4. PMC 1027155. PMID 9203931.
^ Tysk C, Lindberg E, Järnerot G, Flodérus-Myrhed B (1988). "Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking". Gut 29 (7): 990–6. doi:10.1136/gut.29.7.990. PMC 1433769. PMID 3396969.
^ Kirsner JB (1988). "Historical aspects of inflammatory bowel disease". J. Clin. Gastroenterol. 10 (3): 286–97. doi:10.1097/00004836-198806000-00012. PMID 2980764.
^ ^a ^b Agrawal G, Borody TJ, Chamberlin W (2014). "'Global warming' to Mycobacterium avium subspecies paratuberculosis". Future Microbiology 9 (7): 829–832. doi:10.2217/fmb.14.52. ISSN 1746-0913. PMID 25156371.
^ Scribano, ML; Prantera, C (Feb 7, 2013). "Use of antibiotics in the treatment of Crohn's disease.". World journal of gastroenterology : WJG 19 (5): 648–53. doi:10.3748/wjg.v19.i5.648. PMID 23429474.
^ Chamberlin, W; Borody, TJ; Campbell, J (Nov 2011). "Primary treatment of Crohn's disease: combined antibiotics taking center stage.". Expert review of clinical immunology 7 (6): 751–60. doi:10.1586/eci.11.43. PMID 22014016.
^ Bull TJ, Gilbert SC, Sridhar S, Linedale R, Dierkes N, Sidi-Boumedine K, Hermon-Taylor J (2007). "'A novel multi-antigen virally vectored vaccine against Mycobacterium avium subspecies paratuberculosis". PLOS ONE 2 (11): e1229. doi:10.1371/journal.pone.0001229. PMC 2082073. PMID 18043737.
^ Croese J, O'neil J, Masson J, Cooke S, Melrose W, Pritchard D, Speare R (2006). "A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors". Gut 55 (1): 136–7. doi:10.1136/gut.2005.079129. PMC 1856386. PMID 16344586.
^ *Massa F, Monory K (2007). "Endocannabinoids and the gastrointestinal tract". Journal of Endocrinological Investigation 29 ((Suppl)): 47–57. PMID 16751708.
^ Massa F, Storr M, Lutz B (2005). "The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract". Journal of Molecular Medicine 83 (12): 944–54. doi:10.1007/s00109-005-0698-5. PMID 16133420.
^ Izzo AA, Coutts AA (2005). "Cannabinoids and the digestive tract". Handbook of Experimental Pharmacology. Handbook of Experimental Pharmacology 168 (168): 573–98. doi:10.1007/3-540-26573-2_19. ISBN 3-540-22565-X. PMID 16596788.
^ Srinivasan, R; Akobeng, AK (Apr 15, 2009). "Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007350. doi:10.1002/14651858.CD007350.pub2. PMID 19370684.
^ Akobeng, AK; Stokkers, PC (Apr 15, 2009). "Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007351. doi:10.1002/14651858.CD007351.pub2. PMID 19370685.

External links

Wikimedia Commons has media related to Crohn's disease.

Crohn's disease at DMOZ

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における軽症～中等症クローン病の内科的管理の概要 overview of the medical management of mild to moderate crohns disease in adults
2. 成人におけるクローン病の臨床症状、診断、および予後 clinical manifestations diagnosis and prognosis of crohns disease in adults
3. 成人における重症または難治性クローン病の内科的管理の概要 overview of the medical management of severe or refractory crohns disease in adults
4. 小児および思春期におけるクローン病管理の概要 overview of the management of crohns disease in children and adolescents
5. クローン病におけるインフリキシマブ infliximab in crohns disease

English Journal

Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort.

Alatri A1, Schoepfer A2, Fournier N3, Engelberger RP1, Safroneeva E4, Vavricka S5,6, Biedermann L6, Calanca L1, Mazzolai L1; Swiss IBD Cohort Study Group.
Scandinavian journal of gastroenterology.Scand J Gastroenterol.2016 Oct;51(10):1200-5. doi: 10.1080/00365521.2016.1185464. Epub 2016 May 20.
OBJECTIVE: Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is associated with the occurrence of venous thromboembolism (VTE) such as deep vein thrombosis (DVT) and pulmonary embolism (PE). We aimed to assess the prevalence and associated risk factors for
PMID 27211077

Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort.

van den Heuvel TR1,2, Wintjens DS1, Jeuring SF1,2, Wassink MH1, Romberg-Camps MJ3, Oostenbrug LE4, Sanduleanu S1, Hameeteman WH1, Zeegers MP2,5,6, Masclee AA1,2, Jonkers DM1,2, Pierik MJ1,2.
International journal of cancer.Int J Cancer.2016 Sep 15;139(6):1270-80. doi: 10.1002/ijc.30183. Epub 2016 May 31.
The management of inflammatory bowel disease (IBD) has changed since the mid-1990s (e.g., use of thiopurines/anti-TNFα agents, improved surveillance programs), possibly affecting cancer risk. To establish current cancer risk in IBD, updates are warranted from cohorts covering this time span, and de
PMID 27170593

Evolving roles of cross-sectional imaging in Crohn's disease.

Magarotto A1, Orlando S1, Coletta M1, Conte D2, Fraquelli M3, Caprioli F4.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.Dig Liver Dis.2016 Sep;48(9):975-83. doi: 10.1016/j.dld.2016.05.017. Epub 2016 May 30.
The implementation of cross-sectional imaging techniques for the clinical management of Crohn's disease patients has steadily grown over the recent years, thanks to a series of technological advances, including the evolution of contrast media for magnetic resonance, computed tomography and bowel ult
PMID 27338853

Japanese Journal

臨床報告 Crohn病に合併した網膜中心静脈閉塞症の1症例

福田宏美,森秀夫
臨床眼科 68(5), 737-740, 2014-05
NAID 40020081170

炎症性腸疾患(Inflammatory bowel disease: IBD)に対する分子標的治療

内藤裕二,内山和彦,髙木智久
京都府立医科大学雑誌 123(4), 233-245, 2014-04
NAID 40020083451

症例報告 Crohn病に対するTNF-α阻害薬投与中に生じた難治性陰部乾癬様皮疹の女性例

有馬由美,高野裕子,安部文人 [他]
臨床皮膚科 68(4), 313-317, 2014-04
NAID 40020064035

Related Pictures

★リンクテーブル★

リンク元	「クローン病」「ileocolitis」「granulomatous enteritis」
拡張検索	「Crohn disease activity index」
関連記事	「disease」

「クローン病」

Crohn's disease
	Classification and external resources
	The three most common sites of intestinal involvement in Crohn's disease are ileal, ileocolic and colonic.
ICD-10	K50
ICD-9	555
OMIM	266600
DiseasesDB	3178
MedlinePlus	000249
eMedicine	med/477 ped/507 radio/197
Patient UK	Crohn's disease
MeSH	D003424

　　[★]

英: Crohn disease, Crohn's disease
同: Crohn病; 限局性回腸炎 regional ileitis、回腸末端炎、終末回腸炎 terminal ileitis
関: 潰瘍性大腸炎、炎症性腸疾患 inflammatory bowel disease

first aid step1 2006 p.113,140,276,280,283,326,427
see also 消化器系チュートリアルの材料.xls

まとめ

特定疾患治療研究事業に含まれる疾患である(特定疾患)。消化管のあらゆる部位に非連続性に起こる原因不明・全層性の慢性肉芽腫性炎症疾患である。10歳後半から20歳代の若年者に多く、また男性に多い(男女比2:1)。病因は不明であるが、炎症反応の亢進であるかもしれない。病理学的にはリンパ球、形質細胞浸潤を伴う全層性炎症像がみられる。また、非乾酪性類上皮細胞肉芽腫が特徴的である。症状は腹痛、下痢、発熱、体重減少などあり、肛門病変(痔瘻や裂肛)が初発することがある。血液検査では炎症所見(WBC,CRP上昇、赤沈亢進)が見られ、貧血、低栄養の所見、またα1アンチトリプシン試験で異常となる。画像検査では、非連続性の病変が認められ、またアフタ状潰瘍、腸間膜付着側の縦列潰瘍、敷石像、瘻孔形成、肛門病変が認められる。治療は内科的治療が中心である。絶食、栄養療法(成分栄養剤による経腸栄養療法、経静脈栄養。小腸ok)、薬物療法(サラゾスルファピリジン(大腸only)、メサラジン(小腸・大腸ok)。ステロイド(栄養療法・5-アミノサリチル酸不応例)、インフリキシマブ、免疫抑制薬、顆粒球吸着療法(GCAP)が行われる。外科療法は狭窄、膿瘍、肛門病変に対して行われる。(SSUR.535 YN A-62)

比較

Table 15-10. Distinctive Features of Crohn Disease and Ulcerative Colitis*
Feature	Crohn Disease (Small intestine)	Crohn Disease (Colon)	Ulcerative Colitis
Macroscopic
Bowel region	Ileum ± colon†	Colon ± ileum	Colon only
Distribution	Skip lesions	Skip lesions	Diffuse
Stricture	Early	Variable	Late/rare
Wall appearance	Thickened	Variable	Thin
Dilation	No	Yes	Yes
Microscopic
Pseudopolyps	None to slight	Marked	Marked
Ulcers	Deep, linear	Deep, linear	Superficial
Lymphoid reaction	Marked	Marked	Mild
Fibrosis	Marked	Moderate	Mild
Serositis	Marked	Variable	Mild to none
Granulomas	Yes (40% to 60%)	Yes (40% to 60%)	No
Fistulas/sinuses	Yes	Yes	No
Clinical
Fat/vitamin malabsorption	Yes	Yes, if ileum	No
Malignant potential	Yes	Yes	Yes
Response to surgery‡	Poor	Fair	Good

概念

原因不明の炎症性疾患
腸壁全層に肉芽腫形成が見られる
小腸や大腸に縦走潰瘍、敷石像、アフタの形成

病型

病変の存在部位により分類(小腸型、小腸大腸型、大腸型、特殊型など)

頻度：小腸大腸型＞小腸型＞＞大腸型

病理

全層に及ぶ縦走潰瘍、敷石像、アフタの形成

クローン病	腸結核	腸管ベーチェット病
縦走潰瘍	輪状潰瘍	打ち抜き状潰瘍
敷石像	帯状潰瘍	下掘れ状潰瘍

病因

遺伝的因子 + 環境因子(食餌抗原や細菌、ウイルス感染など)　→　免疫異常　→　腸管に慢性炎症性変化

症状

主要症状：腹痛、下痢、発熱、体重減少　←　水様性下痢が一般的で血便が見られることは少ない(QB.A-142)
腹痛(臍周囲部および回盲部痛)、間欠性発熱、下痢、嘔吐、肛門部病変。体重減少、貧血

合併症

1. 消化管合併症:狭窄、瘻孔、痔瘻、肛門周囲膿瘍
2. 消化管外合併症

(a)血液：貧血、低蛋白血症
(b)関節：関節炎、強直性脊椎炎
(c)皮膚：口腔内アフタ、結節性紅斑、壊死性膿皮症
(d)　　：多形滲出性紅斑
(e)眼　：虹彩炎、ぶどう膜炎
(f)栄養代謝：成長障害、微量元素欠乏、ビタミン欠乏
(g)アミロイドーシスなど
(h)悪性腫瘍：腸癌など　←　悪性腫瘍は潰瘍性大腸炎の方が頻度が高い
(i)そのほか：原発性硬化性胆管炎

続発症

ビタミンK欠乏症

検査

腹部単純X線写真：イレウスを疑う症例ではニボーの確認のために重要。クローン病の確定診断にはやくにたたない。
上部消化管内視鏡
下部消化管内視鏡
小腸造影：小腸病変の評価。特に回腸末端の病変、程度、潰瘍、狭窄、瘻孔
腹部造影CT：TNFα阻害薬やステロイドを用いる際には、腹部から触知下腫瘤が腸管の癒着か、膿瘍の合併によるものかを評価する必要がある(QB.A-144)
注腸造影：大腸病変の描出

[show details]

診断

[show details]

(1)

臨床所見

消化管病変

腸病変

　　（a）縦走潰瘍(注1)

　　（b）敷石像(注2)

　　（c）腸管の狭小，狭窄

　　（d）非連続性又は区域性病変(いわゆるskip lesion)

　　（e）内瘻(腸-腸瘻，腸-膀胱瘻，直腸-腟瘻など)

　　（f）外瘻(腸-皮膚瘻)

　　（g）不整形潰瘍

　　（h）多発アフタ(注3)

肛門病変

　　（a）難治性痔瘍

　　（b）肛門周囲膿瘍

　　（c）裂肛

　　（d）潰瘍

　　（e）肛門皮垂(skip tag)など

胃・十二指腸病変

　　（a）多発アフタ

　　（b）潰瘍

　　（c）狭窄など

　　（d）敷石像など

消化管外病変

　　血液：貧血，低蛋白血症

　　関節：腸性関節炎，強直性脊椎炎

　　皮膚：口内アフタ，結節性紅斑，壊死性膿皮症，多形滲出性紅斑など

　　眼：虹彩炎，ぶどう膜炎など

　　栄養代謝：成長障害，微量元素欠乏，ビタミン欠乏(ビタミンB12，葉酸など)，アミロイドーシスなど

　　悪性腫瘍：腸癌など

　　その他：原発性硬化性胆管炎

病理学的所見

切除標本肉眼所見

　　縦走潰瘍(注1)

　　敷石像(注2)

切除標本組織所見

　　非乾酪性類上皮細胞肉芽腫(局所リンパ節にもみられることがある)(注4)

　　全層性炎症(注5)

　　裂溝

　　潰瘍

生検組織所見

　　非乾酪性類上皮細胞肉芽腫(注4)

--------------------------------------------------------------------------------

(注1)腸管の腸軸方向に4～5cm以上の長さを有する潰瘍で活動期潰瘍では，近傍に炎症性ポリープや敷石像を伴うことが多い。虚血性大腸炎で縦走潰瘍を認めることがあるが，炎症性ポリポーシスや敷石像を伴うことは稀である。潰瘍性大腸炎で縦走潰瘍を認めることがあるが，その周辺粘膜は潰瘍性大腸炎に特徴的な所見を呈する。

(注2)縦走潰瘍とその周辺小潰瘍間の大小不同の密集した粘膜隆起であり，密在した炎症性ポリポーシスもこれに含める。虚血性大腸炎の場合，肉眼標本上で浮腫や残存粘膜等が敷石像類似の所見を呈することがあるが，その高さは低く，発赤調が強い。

(注3)クローン病では縦列することがある。

(注4)非乾酪性類上皮細胞肉芽腫は腸結核でも認められることがある。

(注5)主にリンパ球からなる集簇巣が消化管壁全層にみられるもの。

--------------------------------------------------------------------------------

診断の基準

（１）主要所見

　　A. 縦走潰瘍

　　B. 敷石像

　　C. 非乾酪性類上皮細胞肉芽腫

（２）副所見

　　a. 縦列する不整形潰瘍又はアフタ

　　b. 上部消化管と下部消化管の両者に認められる不整形潰瘍又はアフタ

確診例　１主要所見のA又はBを有するもの(注6，7)。

　　　　２主要所見のCと副所見のいずれか１つを有するもの。

疑診例　１副所見のいずれかを有するもの(注8)。

　　　　２主要所見のCのみを有するもの(注9)。

　　　　３主要所見のA又はBを有するが虚血性大腸炎，潰瘍性大腸炎と鑑別ができないもの。

--------------------------------------------------------------------------------

(注6)縦走潰瘍のみの場合，虚血性大腸炎や潰瘍性大腸炎を除外することが必要である。

(注7)敷石像のみの場合，虚血性大腸炎を除外することが必要である。

(注8)副所見bのみで疑診とした場合は同所見が3カ月恒存することが必要である。

(注9)腸結核などの肉芽腫などを有する炎症性疾患を除外することが必要である。

--------------------------------------------------------------------------------

鑑別診断

IMD

潰瘍性大腸炎、腸結核、ベーチェット病、単純性腸潰瘍、虚血性大腸炎、感染性腸炎、薬物性腸炎、アミロイドーシス

治療

YN.A-66

	クローン病	潰瘍性大腸炎
病因？？？	炎症反応亢進	免疫応答の異常
寛解導入	栄養療法
	5-アミノサリチル酸(大: サラゾスルファピリジン、小: メサラジン)	5-アミノサリチル酸(大: サラゾスルファピリジン、小: メサラジン)
	ステロイド	ステロイド
	抗TNF-α抗体
	シプロフロキサシン、メトロニダゾール	ATM療法
	顆粒球吸着療法(白血球除去療法)	顆粒球吸着療法(白血球除去療法)
		免疫抑制薬
緩解維持	在宅経腸栄養法	無治療～5-アミノサリチル酸(大: サラゾスルファピリジン)
	5-アミノサリチル酸
	免疫抑制薬
外科	狭窄、難治性痔瘻	大出血、狭窄、穿孔、中毒性巨大結腸症、癌化

外科療法

狭窄、瘻孔形成、痔瘻の場合に適応となる。
腸切除の後遺症：吸収障害(脂肪＞蛋白＞糖)、[回盲部切除]胆汁酸・ビタミンB12の吸収不良、小腸内細菌異常増殖(結腸からの侵入？)

USMLE

Q book p.290

参考

1.

http://homepage3.nifty.com/mickeym/No.101_200/163kuro.html

2. 病理学コア UC

http://jsp.umin.ac.jp/corepictures2007/09/c01/index.html

3. 株式会社JIMRO　IBDの診断と治療

http://www.jimro.co.jp/ibd/index_ibd.htm

4. クローン病の治療指針　活動期の治療2010

http://mimibukuro.org/cd/medical-guideline08/2/

5. クローン病注腸造影

アフタ病変

http://www.ajronline.org/content/179/4/1029/F14.expansion

縦走潰瘍

http://www.ajronline.org/content/179/4/1029/F12.expansion

偽ポリープ

http://rfs.acr.org/gamuts/data/images/ID1143.htm

国試

103D037、101E019、101E020、101E021

「ileocolitis」

　　[★] 回結腸炎

関: Crohn disease、Crohn's disease、granulomatous colitis、granulomatous enteritis、regional enteritis、regional ileitis、terminal ileitis

「granulomatous enteritis」

　　[★]

肉芽腫性腸炎

関: Crohn disease、Crohn's disease、granulomatous colitis、ileocolitis、regional enteritis、regional ileitis、terminal ileitis

「Crohn disease activity index」

　　[★] クローン病活動指数

「disease」

　　[★]

n.

疾患：illnessより厳密な概念。「ある臓器に明確な障害が確認され、それによって症状が出ているとはっきり説明できる場合」 (PSY.9)

特定の原因、病態生理、症状、経過、予後、病理組織所見が全てそろった場合 (PSY.9)

something that is very wrong with people's attitudes, way of life or with society.

関: ail、ailment、disease entity、disorder、ill、illness、malady、sick、sickness

注意

disease ≠ illness ≠ disorder

[Baumgart2012-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r ^s Baumgart DC, Sandborn WJ (2012). "Crohn's disease". The Lancet 380 (9853): 1590–605. doi:10.1016/S0140-6736(12)60026-9. PMID 22914295.

[NIDDK2013-2] "Crohn's Disease". National Digestive Diseases Information Clearinghouse (NDDIC). July 10, 2013. Retrieved 12 June 2014.

[3] Cho JH, Brant SR (2011). "Recent Insights into the Genetics of Inflammatory Bowel Disease". Gastroenterology 140 (6): 1704–12. doi:10.1053/j.gastro.2011.02.046. PMID 21530736.

[Bact08-4] Dessein R, Chamaillard M, Danese S (2008). "Innate Immunity in Crohnʼs Disease". Journal of Clinical Gastroenterology 42: S144–7. doi:10.1097/MCG.0b013e3181662c90. PMID 18806708.

[5] Stefanelli T, Malesci A, Repici A, Vetrano S, Danese S (2008). "New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets". Current Drug Targets 9 (5): 413–8. doi:10.2174/138945008784221170. PMID 18473770.

[pmid19437144-6] Marks DJ, Rahman FZ, Sewell GW, Segal AW (2010). "Crohn's disease: An immune deficiency state". Clinical reviews in allergy & immunology 38 (1): 20–31. doi:10.1007/s12016-009-8133-2. PMID 19437144.

[7] Casanova JL, Abel L (Aug 31, 2009). "Revisiting Crohn's disease as a primary immunodeficiency of macrophages.". The Journal of experimental medicine 206 (9): 1839–43. doi:10.1084/jem.20091683. PMID 19687225.

[8] Lalande JD, Behr MA (2010). "Mycobacteria in Crohn's disease: How innate immune deficiency may result in chronic inflammation". Expert review of clinical immunology 6 (4): 633–41. doi:10.1586/eci.10.29. PMID 20594136.

[9] Yamamoto-Furusho JK, Korzenik JR (2006). "Crohn's disease: Innate immunodeficiency?". World Journal of Gastroenterology 12 (42): 6751–5. PMID 17106921.

[genetic_link-10] Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ (2008). "Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease". Nature Genetics 40 (8): 955–62. doi:10.1038/ng.175. PMC 2574810. PMID 18587394.

[Cosnes2004-11] Cosnes J (2004). "Tobacco and IBD: Relevance in the understanding of disease mechanisms and clinical practice". Best Practice & Research Clinical Gastroenterology 18 (3): 481–96. doi:10.1016/j.bpg.2003.12.003. PMID 15157822.

[12] Molodecky, NA; Soon, IS; Rabi, DM; Ghali, WA; Ferris, M; Chernoff, G; Benchimol, EI; Panaccione, R; Ghosh, S; Barkema, HW; Kaplan, GG (Jan 2012). "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.". Gastroenterology 142 (1): 46–54.e42; quiz e30. doi:10.1053/j.gastro.2011.10.001. PMID 22001864.

[13] Prideaux, L; Kamm, MA; De Cruz, PP; Chan, FK; Ng, SC (Aug 2012). "Inflammatory bowel disease in Asia: a systematic review.". Journal of Gastroenterology and Hepatology 27 (8): 1266–80. doi:10.1111/j.1440-1746.2012.07150.x. PMID 22497584.

[Hov2012-14] Hovde, Ø; Moum, BA (Apr 21, 2012). "Epidemiology and clinical course of Crohn's disease: results from observational studies.". World journal of gastroenterology : WJG 18 (15): 1723–31. doi:10.3748/wjg.v18.i15.1723. PMC 3332285. PMID 22553396.

[Bur2013-15] Burisch, J; Munkholm, P (Jul 2013). "Inflammatory bowel disease epidemiology.". Current opinion in gastroenterology 29 (4): 357–62. doi:10.1097/MOG.0b013e32836229fb. PMID 23695429.

[16] Lozano, R; Naghavi, M (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.". Lancet 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604.

[CrohnBB-17] Crohn BB, Ginzburg L, Oppenheimer GD (2000). "Regional ileitis: A pathologic and clinical entity. 1932". The Mount Sinai journal of medicine, New York 67 (3): 263–8. PMID 10828911.

[internetmedicin-18] ^ ^a ^b ^c ^d ^e ^f internetmedicin.se > Inflammatorisk tarmsjukdom, kronisk, IBD By Robert Löfberg. Retrieved Oct 2010 Translate.

[HanauerCrohns-19] Hanauer SB, Sandborn W (2001-03-01). "Management of Crohn's disease in adults" (PDF). American Journal of Gastroenterology 96 (3): 635–43. doi:10.1111/j.1572-0241.2001.03671.x. PMID 11280528. Retrieved 2009-11-07.

[Pimentel-20] Pimentel M, Chang M, Chow EJ, Tabibzadeh S, Kirit-Kiriak V, Targan SR, Lin HC (2000). "Identification of a prodromal period in Crohn's disease but not ulcerative colitis". The American Journal of Gastroenterology 95 (12): 3458–62. doi:10.1111/j.1572-0241.2000.03361.x. PMID 11151877.

[21] Crohn's Disease Overview

[healthline-22] Zieve, David; George F Longstreth (October 18, 2009). "Crohn's Disease". ADAM Health Illustrated Encyclopedia. Retrieved 2010-08-16. ^{[verification needed]}

[emed-23] ^ ^a ^b ^c ^d ^e ^f ^g Crohn Disease at eMedicine

[Podolsky-24] Podolsky DK (2002). "Inflammatory Bowel Disease". New England Journal of Medicine 347 (6): 417–29. doi:10.1056/NEJMra020831. PMID 12167685.

[25] Mueller MH, Kreis ME, Gross ML, Becker HD, Zittel TT, Jehle EC (2002). "Anorectal functional disorders in the absence of anorectal inflammation in patients with Crohn's disease". British Journal of Surgery 89 (8): 1027–31. doi:10.1046/j.1365-2168.2002.02173.x. PMID 12153630.

[26] Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (July 30, 2004). "The Gastrointestinal Tract". Robbins and Cotran: Pathologic Basis of Disease (7th ed.). Philadelphia, Pennsylvania: Elsevier Saunders. p. 847. ISBN 0-7216-0187-1.

[27] Taylor BA, Williams GT, Hughes LE, Rhodes J (1989). "The histology of anal skin tags in Crohn's disease: An aid to confirmation of the diagnosis". International Journal of Colorectal Disease 4 (3): 197–9. doi:10.1007/BF01649703. PMID 2769004.

[28] Fix OK, Soto JA, Andrews CW, Farraye FA (2004). "Gastroduodenal Crohn's disease". Gastrointestinal Endoscopy 60 (6): 985. doi:10.1016/S0016-5107(04)02200-X. PMID 15605018.

[Beattie-29] Beattie RM, Croft NM, Fell JM, Afzal NA, Heuschkel RB (2006). "Inflammatory bowel disease". Archives of Disease in Childhood 91 (5): 426–32. doi:10.1136/adc.2005.080481. PMC 2082730. PMID 16632672.

[30] Büller HA (1997). "Problems in diagnosis of IBD in children". The Netherlands Journal of Medicine 50 (2): S8–11. doi:10.1016/S0300-2977(96)00064-2. PMID 9050326.

[pmid8898436-31] O'Keefe SJ (1996). "Nutrition and gastrointestinal disease". Scand. J. Gastroenterol. Suppl. 220: 52–9. doi:10.3109/00365529609094750. PMID 8898436.

[Danese-32] Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A (2005). "Extraintestinal manifestations in inflammatory bowel disease". World Journal of Gastroenterology 11 (46): 7227–36. PMID 16437620.

[Trikudanathan2012-33] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k Trikudanathan G, Venkatesh PG, Navaneethan U (2012). "Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease". Drugs 72 (18): 2333–49. doi:10.2165/11638120-000000000-00000. PMID 23181971.

[Thrash2013-34] Thrash B, Patel M, Shah KR, Boland CR, Menter A (2013). "Cutaneous manifestations of gastrointestinal disease: part II". Journal of the American Academy of Dermatology 68 (2): 211 e1–33. doi:10.1016/j.jaad.2012.10.036. PMID 23317981.

[Bernstein-35] Bernstein M, Irwin S, Greenberg GR (2005). "Maintenance Infliximab Treatment is Associated with Improved Bone Mineral Density in Crohn's Disease". The American Journal of Gastroenterology 100 (9): 2031–5. doi:10.1111/j.1572-0241.2005.50219.x. PMID 16128948.

[Lomer2011-36] Lomer MC (August 2011). "Dietary and nutritional considerations for inflammatory bowel disease". The Proceedings of the Nutrition Society 70 (3): 329–35. doi:10.1017/S0029665111000097. PMID 21450124.

[Gerasimidis2011-37] Gerasimidis K, McGrogan P, Edwards CA (August 2011). "The aetiology and impact of malnutrition in paediatric inflammatory bowel disease". Journal of Human Nutrition and Dietetics 24 (4): 313–26. doi:10.1111/j.1365-277X.2011.01171.x. PMID 21564345.

[pro-38] Crohn's disease. professionals.epilepsy.com. Retrieved July 13, 2007.

[39] MedlinePlus Encyclopedia Small bowel bacterial overgrowth

[MS-40] Zadik Y, Drucker S, Pallmon S (2011). "Migratory stomatitis (ectopic geographic tongue) on the floor of the mouth". Journal of the American Academy of Dermatology 65 (2): 459–60. doi:10.1016/j.jaad.2010.04.016. PMID 21763590.

[Kornbluth-Sachar2004-41] Kornbluth A, Sachar DB (July 2004). "Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee". American Journal of Gastroenterology 99 (7): 1371–85. doi:10.1111/j.1572-0241.2004.40036.x. PMID 15233681. Archived from the original on April 6, 2008. Retrieved 2009-11-07.

[42] Crohn's Disease Overview

[43] "Crohn's diseaseShare on facebookShare on twitterBookmark & SharePrinter-friendly version". 2013-10-13. Retrieved 16 September 2014.

[44] Braat H, Peppelenbosch MP, Hommes DW (August 2006). "Immunology of Crohn's disease". Annals of the New York Academy of Sciences 1072: 135–54. doi:10.1196/annals.1326.039. PMID 17057196.

[45] Henckaerts L, Figueroa C, Vermeire S, Sans M (May 2008). "The role of genetics in inflammatory bowel disease". Curr Drug Targets 9 (5): 361–8. doi:10.2174/138945008784221161. PMID 18473763.

[Marks2006-46] Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW (2006). "Defective acute inflammation in Crohn's disease: a clinical investigation". Lancet 367 (9511): 668–78. doi:10.1016/S0140-6736(06)68265-2. PMID 16503465.

[47] Comalada M, Peppelenbosch MP (September 2006). "Impaired innate immunity in Crohn's disease". Trends Mol Med 12 (9): 397–9. doi:10.1016/j.molmed.2006.07.005. PMID 16890491.

[48] "Crohn's disease has strong genetic link: study". Crohn's and Colitis Foundation of America. 2007-04-16. Retrieved 2009-11-07.

[49] Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH (2001). "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease". Nature 411 (6837): 603–6. doi:10.1038/35079114. PMID 11385577.

[50] Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG (2002). "The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease". Gastroenterology 122 (4): 867–74. doi:10.1053/gast.2002.32415. PMID 11910337.

[51] Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EE, Higgins DE, Schreiber S, Glimcher LH, Blumberg RS (5 September 2008). "XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease". Cell 134 (5): 743–56. doi:10.1016/j.cell.2008.07.021. PMC 2586148. PMID 18775308.

[52] Clevers H (2009). "Inflammatory Bowel Disease, Stress, and the Endoplasmic Reticulum". New England Journal of Medicine 360 (7): 726–27. doi:10.1056/NEJMcibr0809591. PMID 19213688.

[pmid23128233-53] Jostins L, Ripke S, Weersma RK, et al. (2012). "Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease". Nature 491 (7422): 119–24. doi:10.1038/nature11582. PMC 3491803. PMID 23128233.

[54] Marks DJ, Segal AW (January 2008). "Innate immunity in inflammatory bowel disease: a disease hypothesis". J Pathol. 214 (2): 260–6. doi:10.1002/path.2291. PMC 2635948. PMID 18161747.

[55] Cobrin GM, Abreu MT (2005). "Defects in mucosal immunity leading to Crohn's disease". Immunol. Rev. 206: 277–95. doi:10.1111/j.0105-2896.2005.00293.x. PMID 16048555.

[Elson2007-56] Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA (2007). "Monoclonal Anti – Interleukin 23 Reverses Active Colitis in a T Cell – Mediated Model in Mice". Gastroenterology 132 (7): 2359–70. doi:10.1053/j.gastro.2007.03.104. PMID 17570211.

[57] Prescott NJ, Fisher SA, Franke A, Hampe J, Onnie CM, Soars D, Bagnall R, Mirza MM, Sanderson J, Forbes A, Mansfield JC, Lewis CM, Schreiber S, Mathew CG (2007). "A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5". Gastroenterology 132 (5): 1665–71. doi:10.1053/j.gastro.2007.03.034. PMID 17484864.

[58] Moises Velasquez-Manoff (June 29, 2008). "The Worm Turns". The New York Times.

[59] Sartor, R Balfour (2006). "Mechanisms of Disease: Pathogenesis of Crohn's disease and ulcerative colitis". Nature Clinical Practice Gastroenterology & Hepatology 3 (7): 390. doi:10.1038/ncpgasthep0528.

[pmid22508665-60] Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang ZD, Dupont HL, Garneau P, Harel J, Rishniw M, Simpson KW (2013). "Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease". Inflamm. Bowel Dis. 19 (1): 141–50. doi:10.1002/ibd.22971. PMID 22508665.

[61] ttp://www.scirp.org/journal/PaperInformation.aspx?paperID=19619 The many faces of Crohn's Disease: Latest concepts in etiology

[pmid16306778-62] Naser SA, Collins MT (December 2005). "Debate on the lack of evidence of Mycobacterium avium subsp. paratuberculosis in Crohn's disease". Inflamm. Bowel Dis. 11 (12): 1123. doi:10.1097/01.MIB.0000191609.20713.ea. PMID 16306778.

[PMC4064085-63] Naser SA, Sagramsingh SR, Naser AS, and Naser ST (June 2014). "Mycobacterium avium subspecies paratuberculosis causes Crohn's disease in some inflammatory bowel disease patients". World J Gastroenterol. 20 (23): 7403–7415. doi:10.3748/wjg.v20.i23.7403. PMC 4064085.

[64] Glubb DM, Gearry RB, Barclay ML, Roberts RL, Pearson J, Keenan JI, McKenzie J, Bentley RW (2011). "NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease". World Journal of Gastroenterology 17 (23): 2829–37. doi:10.3748/wjg.v17.i23.2829. PMC 3120942. PMID 21734790.

[65] Clancy R, Ren Z, Turton J, Pang G, Wettstein A (2007). "Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion". Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 39 (5): 445–51. doi:10.1016/j.dld.2006.12.006. PMID 17317344.

[66] Nakase H, Tamaki H, Matsuura M, Chiba T, Okazaki K (2011). "Involvement of mycobacterium avium subspecies paratuberculosis in TNF-α production from macrophage: Possible link between MAP and immune response in Crohn's disease". Inflammatory bowel diseases 17 (11): E140–2. doi:10.1002/ibd.21750. PMID 21990211.

[67] Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW (2007). "Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum". The ISME Journal 1 (5): 403–18. doi:10.1038/ismej.2007.52. PMID 18043660.

[68] Sasaki M, Sitaraman SV, Babbin BA, Gerner-Smidt P, Ribot EM, Garrett N, Alpern JA, Akyildiz A, Theiss AL, Nusrat A, Klapproth JM (2007). "Invasive Escherichia coli are a feature of Crohn's disease". Laboratory investigation; a journal of technical methods and pathology 87 (10): 1042–54. doi:10.1038/labinvest.3700661. PMID 17660846.

[69] Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF (2004). "High prevalence of Adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease". Gastroenterology 127 (2): 412–21. doi:10.1053/j.gastro.2004.04.061. PMID 15300573.

[70] Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW (2007). "Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum". The ISME journal () 1 (5): 403–18. doi:10.1038/ismej.2007.52. PMID 18043660.

[71] Nickerson KP, McDonald C (2012). Mizoguchi, Emiko, ed. "Crohn's Disease-Associated Adherent-Invasive Escherichia coli Adhesion is Enhanced by Exposure to the Ubiquitous Dietary Polysaccharide Maltodextrin". PLoS ONE () 7 (12): e52132. doi:10.1371/journal.pone.0052132. PMC 3520894. PMID 23251695.

[72] Martinez-Medina M, Naves P, Blanco J, Aldeguer X, Blanco JE, Blanco M, Ponte C, Soriano F, Darfeuille-Michaud A, Garcia-Gil LJ (2009). "Biofilm formation as a novel phenotypic feature of adherent-invasive Escherichia coli (AIEC)". BMC Microbiology 9: 202. doi:10.1186/1471-2180-9-202. PMC 2759958. PMID 19772580.

[pmid23272151-73] Chargui A, Cesaro A, Mimouna S, Fareh M, Brest P, Naquet P, Darfeuille-Michaud A, Hébuterne X, Mograbi B, Vouret-Craviari V, Hofman P (2012). "Subversion of autophagy in adherent invasive Escherichia coli-infected neutrophils induces inflammation and cell death". PLoS ONE 7 (12): e51727. doi:10.1371/journal.pone.0051727. PMC 3522719. PMID 23272151.

[pmid22848538-74] Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, Bowman D, Scherl EJ, Simpson KW (2012). "Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease". PLoS ONE 7 (7): e41594. doi:10.1371/journal.pone.0041594. PMC 3404971. PMID 22848538.

[75] Barnich N, Darfeuille-Michaud A (January 2007). "Adherent-invasive Escherichia coli and Crohn's disease". Current Opinion in Gastroenterology 23 (1): 16–20. doi:10.1097/MOG.0b013e3280105a38. PMID 17133079.

[76] Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N (March 2007). "Role for protease activity in visceral pain in irritable bowel syndrome". J. Clin. Invest. 117 (3): 636–47. doi:10.1172/JCI29255. PMC 1794118. PMID 17304351.

[77] Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia-Villar R, Bueno L, Vergnolle N (November 2002). "Induction of Intestinal Inflammation in Mouse by Activation of Proteinase-Activated Receptor-2". Am. J. Pathol. 161 (5): 1903–15. doi:10.1016/S0002-9440(10)64466-5. PMC 1850779. PMID 12414536.

[78] Boorom KF, Smith H, Nimri L, Viscogliosi E, Spanakos G, Parkar U, Li LH, Zhou XN, Ok UZ, Leelayoova S, Jones MS (October 2008). "Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection". Parasit Vectors 1 (1): 40. doi:10.1186/1756-3305-1-40. PMC 2627840. PMID 18937874.

[pmid14683664-79] Hugot JP, Alberti C, Berrebi D, Bingen E, Cézard JP (2003). "Crohn's disease: the cold chain hypothesis". Lancet 362 (9400): 2012–5. doi:10.1016/S0140-6736(03)15024-6. PMID 14683664.

[80] "Fridges blamed for Crohn's disease rise". Medical News Today. 2003-12-12.

[81] Forbes A, Kalantzis T (2005). "Crohn's disease: The cold chain hypothesis". International Journal of Colorectal Disease 21 (5): 399–401. doi:10.1007/s00384-005-0003-7. PMID 16059694.

[82] Subramanian S, Roberts CL, Hart CA, Martin HM, Edwards SW, Rhodes JM, Campbell BJ (2007). "Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics". Antimicrobial Agents and Chemotherapy 52 (2): 427–34. doi:10.1128/AAC.00375-07. PMC 2224732. PMID 18070962.

[83] Mpofu CM, Campbell BJ, Subramanian S, Marshall-Clarke S, Hart CA, Cross A, Roberts CL, McGoldrick A, Edwards SW, Rhodes JM (2007). "Microbial Mannan Inhibits Bacterial Killing by Macrophages: A Possible Pathogenic Mechanism for Crohn's Disease". Gastroenterology 133 (5): 1487–98. doi:10.1053/j.gastro.2007.08.004. PMID 17919633.

[84] "New insights into Crohn's Disease".

[scah_out38-85] "Possible links between Crohn's disease and Paratuberculosis". European Commission Directorate-General Health & Consumer Protection. Retrieved 2009-11-07.

[86] Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J (1997). "Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics". Journal of Antimicrobial Chemotherapy 39 (3): 393–400. doi:10.1093/jac/39.3.393. PMID 9096189.

[Shoda-87] Shoda R, Matsueda K, Yamato S, Umeda N (1996). "Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan". The American journal of clinical nutrition 63 (5): 741–5. PMID 8615358.

[88] Lesko SM, Kaufman DW, Rosenberg L, Helmrich SP, Miller DR, Stolley PD, Shapiro S (1985). "Evidence for an increased risk of Crohn's disease in oral contraceptive users". Gastroenterology 89 (5): 1046–9. PMID 4043662.

[89] Reddy D, Siegel CA, Sands BE, Kane S (July 2006). "Possible association between isotretinoin and inflammatory bowel disease". The American journal of gastroenterology 101 (7): 1569–73. doi:10.1111/j.1572-0241.2006.00632.x. PMID 16863562.

[90] Borobio E, Arín A, Valcayo A, Iñarrairaegui M, Nantes O, Prieto C (2004). "[Isotretinoin and ulcerous colitis]". An Sist Sanit Navar (in Spanish; Castilian) 27 (2): 241–3. doi:10.4321/S1137-66272004000300009. PMID 15381956.

[91] Reniers DE, Howard JM (October 2001). "Isotretinoin-induced inflammatory bowel disease in an adolescent". Annals of Pharmacotherapy 35 (10): 1214–6. doi:10.1345/aph.10368. PMID 11675849.

[92] "Crohn's Disease". National Digestive Diseases Information Clearinghouse. Retrieved 13 November 2012.

[93] Lomer MC, Hutchinson C, Volkert S, Greenfield SM, Catterall A, Thompson RP, Powell JJ (December 2004). "Dietary sources of inorganic microparticles and their intake in healthy subjects and patients with Crohn's disease". Br. J. Nutr. 92 (6): 947–55. doi:10.1079/bjn20041276. PMID 15613257.

[94] Powell JJ, Thoree V, Pele LC (October 2007). "Dietary microparticles and their impact on tolerance and immune responsiveness of the gastrointestinal tract". Br. J. Nutr. 98 Suppl 1: S59–63. doi:10.1017/S0007114507832922. PMC 2737314. PMID 17922962.

[Robbins-95] Crawford JM. "The Gastrointestinal tract, Chapter 17". In Cotran RS, Kumar V, Robbins SL. Robbins Pathologic Basis of Disease: 5th Edition. W.B. Saunders and Company, Philadelphia, 1994.

[96] ttp://www.plos.org/media/press/2012/PLoS_%20HMP_Collection_Manuscript_Summaries.pdf

[97] HCP: Pill Cam, Capsule Endoscopy, Esophageal Endoscopy

[98] Scheinfeld NS, Teplitz E, McClain SA (November 2001). "Crohn's disease and lichen nitidus: a case report and comparison of common histopathologic features". Inflammatory Bowel Diseases 7 (4): 314–8. doi:10.1097/00054725-200111000-00006. PMID 11720321.

[Vienna-99] Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR (2007). "A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998". Inflammatory Bowel Diseases 6 (1): 8–15. doi:10.1002/ibd.3780060103. PMID 10701144.

[phenotypes-100] Dubinsky MC, Fleshner PP (2003). "Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes". Current Treatment Options in Gastroenterology 6 (3): 183–200. doi:10.1007/s11938-003-0001-1. PMID 12744819.

[Hara2006-101] Hara AK, Leighton JA, Heigh RI, Sharma VK, Silva AC, De Petris G, Hentz JG, Fleischer DE (2005). "Crohn Disease of the Small Bowel: Preliminary Comparison among CT Enterography, Capsule Endoscopy, Small-Bowel Follow-through, and Ileoscopy". Radiology 238 (1): 128–34. doi:10.1148/radiol.2381050296. PMID 16373764.

[102] Triester SL, Leighton JA, Leontiadis GI, Gurudu SR, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK (2006). "A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease". The American Journal of Gastroenterology 101 (5): 954–64. doi:10.1111/j.1572-0241.2006.00506.x. PMID 16696781.

[103] Dixon PM, Roulston ME, Nolan DJ (1993). "The small bowel enema: A ten year review". Clinical Radiology 47 (1): 46–8. doi:10.1016/S0009-9260(05)81213-9. PMID 8428417.

[104] Carucci LR, Levine MS (2002). "Radiographic imaging of inflammatory bowel disease". Gastroenterology Clinics of North America 31 (1): 93–117, ix. doi:10.1016/S0889-8553(01)00007-3. PMID 12122746.

[105] Rajesh A, Maglinte DD (2006). "Multislice CT enteroclysis: technique and clinical applications". Clinical Radiology 61 (1): 31–9. doi:10.1016/j.crad.2005.08.006. PMID 16356814.

[106] Zissin R, Hertz M, Osadchy A, Novis B, Gayer G (2005). "Computed Tomographic Findings of Abdominal Complications of Crohn's Disease—Pictorial Essay" (PDF). Canadian Association of Radiologists Journal 56 (1): 25–35. PMID 15835588. Archived from the original on April 6, 2008. Retrieved 2009-11-07.

[107] Mackalski BA, Bernstein CN (2005). "New diagnostic imaging tools for inflammatory bowel disease". Gut 55 (5): 733–41. doi:10.1136/gut.2005.076612. PMC 1856109. PMID 16609136.

[Goh-108] Goh J, O'Morain CA (2003). "Nutrition and adult inflammatory bowel disease". Alimentary Pharmacology and Therapeutics 17 (3): 307–20. doi:10.1046/j.1365-2036.2003.01482.x. PMID 12562443.

[109] Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R (2006). "Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn's Disease". Clinical Gastroenterology and Hepatology 4 (7): 882–7. doi:10.1016/j.cgh.2006.02.003. PMID 16630759.

[110] Kaila B, Orr K, Bernstein CN (2005). "The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease". The Canadian Journal of Gastroenterology 19 (12): 717–21. PMID 16341311. Retrieved 2006-07-02.

[111] Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y (2005). "Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease". Gut 54 (9): 1232–6. doi:10.1136/gut.2004.060228. PMC 1774672. PMID 16099791.

[112] Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S (2007). "New serological markers in inflammatory bowel disease are associated with complicated disease behaviour". Gut 56 (10): 1394–403. doi:10.1136/gut.2006.108043. PMC 2000264. PMID 17456509.

[113] Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J, Lakatos PL (2008). "New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort". The American Journal of Gastroenterology 103 (3): 665–81. doi:10.1111/j.1572-0241.2007.01652.x. PMID 18047543.

[114] Seow CH, Stempak JM, Xu W, Lan H, Griffiths AM, Greenberg GR, Steinhart AH, Dotan N, Silverberg MS (2009). "Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype". Am J Gastroenterol 104 (6): 1426–34. doi:10.1038/ajg.2009.79. PMID 19491856.

[115] Dotan I (2007). "Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification". Expert Rev Gastroenterol Hepatol 1 (2): 265–74. doi:10.1586/17474124.1.2.265. PMID 19072419.

[116] Broomé U, Bergquist A (February 2006). "Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer". Seminars in Liver Disease 26 (1): 31–41. doi:10.1055/s-2006-933561. PMID 16496231.

[Baumgart-117] Baumgart DC, Sandborn WJ (May 2007). "Inflammatory bowel disease: clinical aspects and established and evolving therapies.". The Lancet 369 (9573): 1641–57. doi:10.1016/S0140-6736(07)60751-X. PMID 17499606. Retrieved 2009-11-04.

[pmid12147095-118] Shepherd NA (August 2002). "Granulomas in the diagnosis of intestinal Crohn's disease: a myth exploded?". Histopathology 41 (2): 166–8. doi:10.1046/j.1365-2559.2002.01441.x. PMID 12147095.

[pmid12121237-119] Mahadeva U, Martin JP, Patel NK, Price AB (July 2002). "Granulomatous ulcerative colitis: a re-appraisal of the mucosal granuloma in the distinction of Crohn's disease from ulcerative colitis". Histopathology 41 (1): 50–5. doi:10.1046/j.1365-2559.2002.01416.x. PMID 12121237.

[agabegi2nd-120] Pages 152-156 (Section: Inflammatory bowel disease(IBD)) in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 0-7817-7153-6.

[pmid20067425-121] Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M (2010). "Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials". Clin. Infect. Dis. 50 (4): 473–80. doi:10.1086/649923. PMID 20067425.

[122] [1] Section "Antibiotics and Ulcerative Colitis" in: Prantera C, Scribano ML (2009). "Antibiotics and probiotics in inflammatory bowel disease: why, when, and how". Curr. Opin. Gastroenterol. 25 (4): 329–33. doi:10.1097/MOG.0b013e32832b20bf. PMID 19444096.

[WebMD-123] Fries, WS; Nazario, B (2007-05-16). "Crohn's Disease: 54 Tips to Help You Manage". WebMD. Retrieved 2008-02-14.

[124] Escott-Stump, Sylvia (2008). Nutrition and Diagnosis-Related Care, 7th edition. Baltimore, MD: Lippincott Williams & Wilkins. pp. 1020 (pp 431). ISBN 978-1-60831-017-3.

[Shanahan-125] Shanahan, Fergus (1 January 2002). "Crohn's disease". The Lancet 359 (9300): 62–69. doi:10.1016/S0140-6736(02)07284-7.

[126] "FDA Approves Cimzia to Treat Crohn's Disease" (Press release). U.S. Food and Drug Administration (FDA). April 22, 2008. Retrieved 2009-11-05.

[Sandborn2005-127] Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P (2005). "Natalizumab Induction and Maintenance Therapy for Crohn's Disease". New England Journal of Medicine 353 (18): 1912–25. doi:10.1056/NEJMoa043335. PMID 16267322.

[MacDonald2007-128] MacDonald JK, McDonald JW (2007). MacDonald, John K, ed. "Natalizumab for induction of remission in Crohn's disease". Cochrane Database of Systematic Reviews (1): CD006097. doi:10.1002/14651858.CD006097.pub2. PMID 17253580. CD006097.

[OHCM-129] Longmore, Murray; Ian Wilkinson; Tom Turmezei; Chee Kay Cheung (2007). Oxford Handbook of Clinicial Medicine (7th ed.). Oxford University Press. pp. 266–7. ISBN 0-19-856837-1.

[Mowat2011-130] Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S (May 2011). "Guidelines for the management of inflammatory bowel disease in adults". Gut 60 (5): 571–607. doi:10.1136/gut.2010.224154. PMID 21464096.

[ReferenceA-131] Goddard AF, James MW, McIntyre AS, Scott BB (2011). "Guidelines for the management of iron deficiency anaemia". Gut 60 (10): 1309–1316. doi:10.1136/gut.2010.228874. PMID 21561874.

[ReferenceB-132] Inflamm Bowel Dis Volume 13, Number 12, December 2007

[133] Tresca, AJ (2007-01-12). "Resection Surgery for Crohn's Disease". About.com. Retrieved 2008-02-14.

[pmid8918424-134] Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA (1996). "Reoperative rates for Crohn's disease following strictureplasty. Long-term analysis". Dis. Colon Rectum 39 (11): 1199–203. doi:10.1007/BF02055108. PMID 8918424.

[pmid2394349-135] Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M (October 1990). "Predictability of the postoperative course of Crohn's disease". Gastroenterology 99 (4): 956–63. PMID 2394349.

[pmid24917974-136] Yamamoto T, Bamba T, Umegae S, Matsumoto K (August 2013). "The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn's disease: A 5-year prospective cohort study". United European Gastroenterol J 1 (4): 294–8. doi:10.1177/2050640613495197. PMC 4040796. PMID 24917974.

[137] Short Bowel Syndrome as defined by the National Institute of Diabetes and Digestive and Kidney Diseases

[138] Hofmann AF (1967). "The syndrome of ileal disease and the broken enterohepatic circulation: cholerhetic enteropathy.". Gastroenterology 52 (4): 752–7. PMID 5337211.

[139] Rhodes, M (2006-10-24). "Intestinal transplant for Crohn's disease". Everyday Health. Retrieved 2009-03-22.

[140] Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ (2006). "European evidence based consensus on the diagnosis and management of Crohn's disease: special situations". Gut. 55 Suppl 1 (Suppl 1): i36–58. doi:10.1136/gut.2005.081950c. PMC 1859996. PMID 16481630.

[cam_germ-141] "Use of complementary and alternative medicine in Germany – a survey of patients with inflammatory bowel disease". BioMed Central. Retrieved 21 September 2010. "At the same time, further clinical studies assessing the most commonly used CAM therapies are urgently needed. Research in CAM offers the chance to discover new treatment options in the management of IBD but may also protect patients from ineffective and expensive 'pseudo'-therapies."

[Joos-142] Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, Hahn EG, Schuppan D (2004). "Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study". Digestion 69 (3): 131–9. doi:10.1159/000078151. PMID 15114043.

[special_situations-143] Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ (2006). "The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations". Gut 55 (Suppl 1): i36–i58. doi:10.1136/gut.2005.081950c. PMC 1859996. PMID 16481630. "the colitis activity index fell significantly in the treatment group compared to the sham acupuncture group. However, recruitment did not reach its target and the number of patients was small." ^{[verification needed]}

[Ernst_2011-144] Ernst, E.; Lee, Myeong Soo; Choi, Tae-Young (2011). "Acupuncture: Does it alleviate pain and are there serious risks? A review of reviews" (PDF). Pain 152 (4): 755–764. doi:10.1016/j.pain.2010.11.004. ISSN 0304-3959. PMID 21440191.

[gut_alt-145] Smart HL, Mayberry JF, Atkinson M (1986). "Alternative medicine consultations and remedies in patients with the irritable bowel syndrome". Gut 27 (7): 826–8. doi:10.1136/gut.27.7.826. PMC 1433575. PMID 3755416.

[146] "Crohn's disease - Prognosis". University of Maryland Medical Centre. Retrieved 19 October 2012.

[Canavan-147] Canavan C, Abrams KR, Mayberry J (2006). "Meta-analysis: Colorectal and small bowel cancer risk in patients with Crohn's disease". Alimentary Pharmacology and Therapeutics 23 (8): 1097–104. doi:10.1111/j.1365-2036.2006.02854.x. PMID 16611269.

[148] Prevalence defined as at least 5 health care contacts in a 10 year period for the condition, according to: Greenstein AJ, Janowitz HD, Sachar DB (September 1976). "The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients". Medicine (Baltimore) 55 (5): 401–12. doi:10.1097/00005792-197609000-00004. PMID 957999.

[149] Enterovesical Fistula at eMedicine

[150] Ekbom A, Helmick C, Zack M, Adami HO (1990). "Increased risk of large-bowel cancer in Crohn's disease with colonic involvement". Lancet 336 (8711): 357–9. doi:10.1016/0140-6736(90)91889-I. PMID 1975343.

[151] Collins PD, Mpofu C, Watson AJ, Rhodes JM (2006). Watson, Alastair J, ed. "Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease". Cochrane Database Syst Rev (2): CD000279. doi:10.1002/14651858.CD000279.pub3. PMID 16625534.

[152] Zisman TL, Rubin DT (2008). "Colorectal cancer and dysplasia in inflammatory bowel disease". World Journal of Gastroenterology 14 (17): 2662–9. doi:10.3748/wjg.14.2662. PMC 2709054. PMID 18461651.

[153] Evans JP, Steinhart AH, Cohen Z, McLeod RS (2003). "Home Total Parenteral Nutrition an Alternative to Early Surgery for Complicated Inflammatory Bowel Disease". Journal of Gastrointestinal Surgery 7 (4): 562–6. doi:10.1016/S1091-255X(02)00132-4. PMID 12763417.

[154] "Complications of Crohn's Disease". Centocor Ortho Biotech. Retrieved 2009-11-07.

[155] Carrillo, Maria (September 1, 1985). "Man of Many Problems Comes to City for Help". Richmond Times-Dispatch (Richmond, Virginia, USA). p. B1.

[156] "Kay, Laura Lynn". Richmond Times-Dispatch (Richmond, Virginia, USA). April 3, 2014.
Loebenberg, Priscilla (March 2, 2014). "Doris L. Johnson, 82, of Westminster". Carroll County Times (Westminster, Maryland, USA).
Berrier Jr., Ralph (December 31, 2013). "In memoriam: Dan Hodges Jr.". The Roanoke Times (Roanoke, Virginia, USA).
"Cynthia Meredith Routt". Daily Press (Newport News, Virginia, USA). May 4, 2014. p. A11.

[157] Kaplan, C (2005-10-21). "IBD and Pregnancy: What You Need to Know". Crohn's and Colitis Foundation of America. Archived from the original on 2012-02-17. Retrieved 2009-11-07.

[Hiatt-158] Hiatt RA, Kaufman L (1988). "Epidemiology of inflammatory bowel disease in a defined northern California population". Western Journal of Medicine 149 (5): 541–6. PMC 1026530. PMID 3250100.

[159] Moum B, Vatn MH, Ekbom A, Aadland E, Fausa O, Lygren I, Stray N, Sauar J, Schulz T (1996). "Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists". Scandinavian Journal of Gastroenterology 31 (4): 355–61. doi:10.3109/00365529609006410. PMID 8726303.

[160] Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M (1996). "Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)". Gut 39 (5): 690–7. doi:10.1136/gut.39.5.690. PMC 1383393. PMID 9014768.

[Yang-161] Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI (1993). "Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews". Gut 34 (4): 517–24. doi:10.1136/gut.34.4.517. PMC 1374314. PMID 8491401.

[pmid19067428-162] Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J (2009). "Effects of light smoking consumption on the clinical course of Crohn's disease". Inflamm. Bowel Dis. 15 (5): 734–41. doi:10.1002/ibd.20828. PMID 19067428.

[163] "Crohn's disease manifests differently in boys and girls". Crohn's and Colitis Foundation of America.

[164] "Who is affected by Crohn's disease". Healthwise.

[165] Satsangi J, Jewell DP, Bell JI (1997). "The genetics of inflammatory bowel disease". Gut 40 (5): 572–4. PMC 1027155. PMID 9203931.

[166] Tysk C, Lindberg E, Järnerot G, Flodérus-Myrhed B (1988). "Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking". Gut 29 (7): 990–6. doi:10.1136/gut.29.7.990. PMC 1433769. PMID 3396969.

[167] Kirsner JB (1988). "Historical aspects of inflammatory bowel disease". J. Clin. Gastroenterol. 10 (3): 286–97. doi:10.1097/00004836-198806000-00012. PMID 2980764.

[Agrawal_G.2C_Borody_TJ.2C_Chamberlin_W_2014_829.E2.80.93832-168] Agrawal G, Borody TJ, Chamberlin W (2014). "'Global warming' to Mycobacterium avium subspecies paratuberculosis". Future Microbiology 9 (7): 829–832. doi:10.2217/fmb.14.52. ISSN 1746-0913. PMID 25156371.

[169] Scribano, ML; Prantera, C (Feb 7, 2013). "Use of antibiotics in the treatment of Crohn's disease.". World journal of gastroenterology : WJG 19 (5): 648–53. doi:10.3748/wjg.v19.i5.648. PMID 23429474.

[170] Chamberlin, W; Borody, TJ; Campbell, J (Nov 2011). "Primary treatment of Crohn's disease: combined antibiotics taking center stage.". Expert review of clinical immunology 7 (6): 751–60. doi:10.1586/eci.11.43. PMID 22014016.

[171] Bull TJ, Gilbert SC, Sridhar S, Linedale R, Dierkes N, Sidi-Boumedine K, Hermon-Taylor J (2007). "'A novel multi-antigen virally vectored vaccine against Mycobacterium avium subspecies paratuberculosis". PLOS ONE 2 (11): e1229. doi:10.1371/journal.pone.0001229. PMC 2082073. PMID 18043737.

[172] Croese J, O'neil J, Masson J, Cooke S, Melrose W, Pritchard D, Speare R (2006). "A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors". Gut 55 (1): 136–7. doi:10.1136/gut.2005.079129. PMC 1856386. PMID 16344586.

[173] *Massa F, Monory K (2007). "Endocannabinoids and the gastrointestinal tract". Journal of Endocrinological Investigation 29 ((Suppl)): 47–57. PMID 16751708.

[174] Massa F, Storr M, Lutz B (2005). "The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract". Journal of Molecular Medicine 83 (12): 944–54. doi:10.1007/s00109-005-0698-5. PMID 16133420.

[175] Izzo AA, Coutts AA (2005). "Cannabinoids and the digestive tract". Handbook of Experimental Pharmacology. Handbook of Experimental Pharmacology 168 (168): 573–98. doi:10.1007/3-540-26573-2_19. ISBN 3-540-22565-X. PMID 16596788.

[176] Srinivasan, R; Akobeng, AK (Apr 15, 2009). "Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007350. doi:10.1002/14651858.CD007350.pub2. PMID 19370684.

[177] Akobeng, AK; Stokkers, PC (Apr 15, 2009). "Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007351. doi:10.1002/14651858.CD007351.pub2. PMID 19370685.

Crohn's disease
Classification and external resources
The three most common sites of intestinal involvement in Crohn's disease are ileal, ileocolic and colonic.^[1]
ICD-10	K50
ICD-9	555
OMIM	266600
DiseasesDB	3178
MedlinePlus	000249
eMedicine	med/477 ped/507 radio/197
Patient UK	Crohn's disease
MeSH	D003424

匿名

検索

案内

Crohn disease

WordNet

PrepTutorEJDIC

Wikipedia preview

wiki en

Contents

Signs and symptoms

Gastrointestinal

Systemic

Extraintestinal

Cause

Genetics

Immune system

Microbes

Environmental factors

Pathophysiology

Diagnosis

Classification

Endoscopy

Radiologic tests

Blood tests

Comparison with ulcerative colitis

Management

Lifestyle changes

Medication

Surgery

Alternative medicine

Prognosis

Complications

Epidemiology

History

Research

References

External links

UpToDate Contents

English Journal

Japanese Journal

Related Links

Related Pictures

★リンクテーブル★

「クローン病」

まとめ

比較

概念

病型

病理

病因

症状

合併症

続発症

検査

診断

臨床所見

消化管病変

消化管外病変

病理学的所見

切除標本肉眼所見

切除標本組織所見

生検組織所見

診断の基準

（１）主要所見

（２）副所見

鑑別診断

治療

YN.A-66

外科療法

USMLE

参考

国試

「ileocolitis」

「granulomatous enteritis」

「Crohn disease activity index」

「disease」